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ABSTRACT 
Parkinson’s disease is a common neurodegenerative disorder resulting from 
progressive loss of dopaminergic neurons in the substantia nigra pars compacta region of 
the midbrain. Mitochondrial dysfunction and oxidative stress are major contributors to 
this disease.  Currently there is no treatment to halt the progression of Parkinson’s 
disease; there are only drugs for symptomatic relief.  Previously, prophylactic treatment 
with a water-soluble formulation of coenzyme Q10 was shown to reduce the loss of 
dopaminergic neurons in the substantia nigra and ameliorate symptoms in a paraquat-
induced rat model of Parkinson’s disease.  In this work, delivery of CoQ10 by the water-
soluble formulation shows increased bioavailability in various rat tissues, including the 
brain.  Also observed is a decrease in the loss of dopaminergic neurons in the substantia 
nigra by therapeutic water-soluble CoQ10 supplementation in a rat model. Hence, this 
formulation of CoQ10 may be used to slow or halt the progression of Parkinson’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 v 
DEDICATION 
This work is dedicated to my family and those who have been affected with Parkinson’s 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
ACKNOWLEDGEMENTS 
 First and foremost, I would like to thank my supervisor, Dr. Siyaram Pandey for 
giving me the opportunity to work on this project.  His guidance and patience have 
always been greatly appreciated, but it is his enthusiasm for our work that motivated and 
inspired me everyday.  It has been a rewarding experience beyond any expectations. 
 Thank you to our collaborators Dr. Jerome Cohen, Dr. Marianna Siikorska and 
Dr. Jagdeep Sandhu for their generous help and support.  Thank you also to my 
committee members, Dr. Boffa and Dr. Zielinski for their advice and for reading my 
thesis.  A very big thank you to Dr. Lee for all the time and hard work she put into 
reading my thesis and especially for the mentoring.  Thank you to Ms. Elaine Rupke for 
all her help and expertise with the animals.  Thank you to Joe Lichaa for his continuous 
tech support and teaching me how to take apart things and put them back together again.  
Thank you to Marlene Bezaire, Cathy Wilson and Beth Kickham in the Chemistry and 
Biochemistry office for answering the millions of questions I asked every day and for 
always keeping me on track. 
 I would like to extend an enormous thanks to all the members of the Pandey lab 
group.  Especially Mallika Somayajulu-nitu for sharing her wisdom of the PD rat lab 
world and all her advice.  Thank you to the undergraduates who put in numerous hours at 
the lab and made the work more enjoyable for all of us: Kristen Church, Natasha Rafo, 
Parvati Dadwal, Jessica Smith, Kate Harrison, Samantha Leahy and Harshil Jasra.  
Thank you also to Krithika Muthukumaran, good luck with the future of this project.  
Thank you to the other graduate students: Carly Moysiak, Sudipa Chatterjee, Pam 
Ovadje and Dennis Ma.  I would like to the thank Dr. Cohen’s lab for doing all the 
 vii 
behavioural work with the rats; especially, Dan Loatpin and Joe Barkho thanks for being 
my “rat boy.” 
 I would like to give a special thank you to Mr. Joseph Szcesei and his family for 
their generous support of this project. 
 Last, but not least I would like to thank my family: my mom, my dad, and my sister 
for their love, encouragement and continuous support.  Thanks for putting up with me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
FOREWORD 
 The following collaborators made contributions to this project: 
 Harvey Miller at the National Research Council of Canada produced data 
regarding bioavailability and pharmacokinetics of water-soluble coenzyme Q10. Harvey 
conducted high-performance liquid chromatography separations of blood plasma and 
tissue samples, and subsequently quantified proteins and CoQ10 levels for each sample by 
Pierce Comassie plus plate reader assay and UVC detection, respectively. 
 
 Dr. Cohen and laboratory team (Joe Barkho, Dan Lopatin and others) at the 
University of Windsor Psychology Department cared for animals, maintained group 
cages, and conducted all behavioural tests.  Dr. Cohen consolidated data, constructed 
graphs, and performed statistical analysis of the results of those tests. 
 
 Zymes LLC. manufactured and provided stock solutions of water-soluble 
coenzyme Q10 and polyoxyethanyl-α-tocopheryl sebacate (PTS). 
 
 Undergraduates (Kristen Church, Natasha Rafo, Parvati Dadwal, Samathan Leahy, 
Jessica Smith, Kate Harrison, and Harshil Jasra) assisted with rat injections, dissections, 
sectioning of brain tissue, tyrosine hydroxylase immunohistochemistry, and Stereologer 
cell counting. 
 
 
 
 
 
 ix 
TABLE OF CONTENTS 
DECLARATION OF ORIGINALITY .............................................................................. iii 
ABSTRACT ....................................................................................................................... iv 
DEDICATION .................................................................................................................... v 
ACKNOWLEDGEMENTS ............................................................................................... vi 
FOREWORD ................................................................................................................... viii 
LIST OF TABLES ........................................................................................................... xiii 
LIST OF FIGURES ......................................................................................................... xiv 
LIST OF APPENDICES .................................................................................................. xvi 
LIST OF ABBREVIATIONS ......................................................................................... xvii 
 
CHAPTER I: INTRODUCTION 
1.1. Parkinson’s Disease ............................................................................................ 1 
1.2. Synthesis, Release and Metabolism of Dopamine .............................................. 2 
1.3 The Nigrostriatal Pathway ................................................................................... 4 
1.4 Etiology of Parkinson’s Disease .......................................................................... 7 
1.5 Genetic Causes of Parkinson’s Disease ............................................................... 9 
 1.5.1 Alpha-synuclein ...................................................................................... 9 
 1.5.2 PARK Gene Family .............................................................................. 10 
1.6 Toxin and Environmental Causes of Parkinson’s disease ................................. 12 
 1.6.1 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) ....................... 12 
 1.6.2. Paraquat ................................................................................................ 14 
 1.6.3. Rotenone .............................................................................................. 16 
 1.6.4. Oxidopamine/6-hydroxydopamine (6-OHDA) .................................... 17 
1.7 Mechanism of Neurodegeneration ..................................................................... 18 
 x 
 1.7.1. Oxidative Stress Leading to Mitochondrial Dysfunction .................... 19 
 1.7.2. Oxidative Stress in Parkinson’s Disease .............................................. 20 
 1.7.3. Neuroinflammation .............................................................................. 20 
1.8. Antioxidants as Possible Therapeutic Agents for Parkinson’s Disease ............ 21 
 1.8.1. Vitamin E ............................................................................................. 22 
 1.8.2. Coenzyme C10 (CoQ10) ........................................................................ 23 
 1.8.3. Water-soluble Coenzyme Q10 .............................................................. 25 
1.9. Role of Glial Cells in Preventing Neuronal Cell Death .................................... 27 
 1.9.1. Neurotrophic Factors ............................................................................ 27 
1.10. Objectives ....................................................................................................... 29 
 
CHAPTER II: METHODS 
 2.1. Animals and Animal Care ................................................................................ 30 
2.2. Behavioural Assessment ................................................................................... 30 
 2.2.1. Pole Test ............................................................................................... 30 
 2.2.2. Turn Around Test ................................................................................. 31 
2.3. Experimental Design ........................................................................................ 31 
 2.3.1. Experiment I: Assessment of Paraquat Toxicity Over Time ............... 31 
 2.3.2. Experiment II: Bioavailability and Pharmacokinetics of WS-CoQ10 .. 32 
 2.3.3. Experiment III: Assessment of Intravenous WS-CoQ10 Delivery ....... 33 
 2.3.4. Experiment IV: Assessment of WS-CoQ10 as a Therapeutic Treatment 
of Parkinson’s Disease ................................................................................... 34 
2.4. Dissections ........................................................................................................ 35 
 2.4.1. General Supplies .................................................................................. 35 
 2.4.2. Tissue Collection for Immunohistochemistry and Biochemical Assays
 ........................................................................................................................ 36 
 xi 
 2.4.3. Brain Harvesting .................................................................................. 37 
2.5. Immunohistochemistry ..................................................................................... 38 
 2.5.1. Immunohistochemical Reagents .......................................................... 38 
 2.5.2. Dehydration and Paraffin Embedding .................................................. 38 
 2.5.3. Tissue Sectioning ................................................................................. 39 
 2.5.4. Slide Preparation .................................................................................. 39 
 2.5.5. Bright-field Immunohistochemistry using 3,3’-diaminobenzidine 
(DAB) ............................................................................................................. 40 
 2.5.6. Stereologer Software ............................................................................ 41 
2.6. Biochemical Assays .......................................................................................... 41 
 2.6.1. Biochemical Reagents .......................................................................... 41 
 2.6.2. Tissue Homogenization ........................................................................ 43 
 2.6.3. Sample Preparation .............................................................................. 43 
 2.6.4. Bradford Assay .................................................................................... 44 
 2.6.5. SDS-PAGE Western Blot .................................................................... 44 
 2.6.6. Glutathione Assay ................................................................................ 45 
 2.6.7. Lipid Peroxidation ................................................................................ 46 
2.7. Statistical Analysis ............................................................................................ 46 
 
CHAPTER III: RESULTS 
 3.1. Paraquat Toxicity Suggests Progress Dopaminergic Neuronal Cell Death ...... 47 
3.2. Bioavailability and Pharmacokinetics of WS-CoQ10 ....................................... 50 
3.3. Injecting WS-CoQ10 Intravenously ................................................................... 53 
3.4. Evaluation of WS-CoQ10 as a Therapeutic Neuroprotection ............................ 53 
 3.4.1. Dopaminergic neurons are protected by WS-CoQ10 ............................ 54 
 3.4.2. Biochemical markers of oxidative stress ............................................. 56 
 xii 
 3.4.3. Behavioural Results ............................................................................. 58 
 
CHAPTER IV: DISCUSSION 
4.1. Overview ........................................................................................................... 60 
4.2. Animal Models of Parkinson’s Disease ............................................................ 60 
4.3. Paraquat as an environmental toxin-induced model for Parkinson’s Disease .. 62 
4.4. Assessment of paraquat toxicity ....................................................................... 63 
4.5. Assessing the bioavailability of CoQ10 with a water-soluble delivery system . 64 
4.6. Evaluation of the efficacy of WS-CoQ10 as a therapeutic neuroprotective agent
 ........................................................................................................................ 67 
4.7. Potential mechanisms of WS-CoQ10 neuroprotection ...................................... 68 
4.8. Future Studies ................................................................................................... 70 
4.9. Conclusion ........................................................................................................ 73 
 
REFERENCES ................................................................................................................. 74 
APPENDICES .................................................................................................................. 93 
VITA AUCTORIS .......................................................................................................... 103 
 
 
 
 
 
 
 
 
 xiii 
LIST OF TABLES 
Table 1:  Parkinsonism genetics ................................................................................. 9 
Table 2:  Effects of antioxidant on neurodegenerative diseases ............................... 22 
Table 3:  Groups for Experiment 1: Assessment of paraquat toxicity over time ..... 32 
Table 4:  Groups for Experiment II: Bioavailability and pharmacokinetics of       
WS-CoQ10 ................................................................................................. 33 
Table 5:  Groups for Experiment IV: Assessment of WS-CoQ10 as a therapeutic 
treatment of Parkinson’s disease ............................................................... 35 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
LIST OF FIGURES 
 
Figure 1:  Dopamine synthesis......................................................................................2 
Figure 2:  Neurotransmitting dopamine........................................................................3 
Figure 3:  Dopaminergic pathways...............................................................................4 
Figure 4:  Nigrostriatal pathway...................................................................................5 
Figure 5:  Basal ganglia circuitry..................................................................................6 
Figure 6:  Neurotoxins................................................................................................12 
Figure 7:  MPTP metabolism......................................................................................14 
Figure 8:  Reduction-oxidation cycling of paraquat...................................................15 
Figure 9:  Tyrosine hydroxylase positive neurons following oxidopamine injections 
....................................................................................................................18 
Figure 10:  Mitochondria under oxidative stress..........................................................19 
Figure 11:  GSH and Vitamin E interaction.................................................................23 
Figure 12:  Involvement of CoQ10 in the electron transport chain...............................24 
Figure 13:  Water-soluble formulation of coenzyme Q10.............................................26 
Figure 14:  Neurotrophin receptors...............................................................................28 
Figure 15:  Timeline for Experiment I: Assessment of paraquat toxicity over time....32 
Figure 16:  Timeline for Experiment II: Bioavailability and pharmacokinetics of  
WS-CoQ10..................................................................................................33 
Figure 17:  Timeline for Experiment IV: Assessment of WS-CoQ10 as a therapeutic  
treatment of PD..........................................................................................35 
Figure 18:  Paraquat injections suggest progressive loss of dopaminergic 
neurons.......................................................................................................49 
Figure 19:  Bioavailability and pharmacokinetics of WS-CoQ10.................................52 
 xv 
Figure 20:  Neuroprotection of dopaminergic neurons by WS-CoQ10.........................55 
Figure 21:   Markers of oxidative stress........................................................................57 
Figure 22:  Pole Test.....................................................................................................59 
Figure 23:  Vertical Climb-up Test...............................................................................59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
LIST OF APPENDICES 
Appendix A: Tyrosine Hydroxylase Immunohistochemistry Protocol  
Troubleshoooting........................................................................................93 
Appendix B: Additional Behavioural Tests.....................................................................94 
Appendix C: Additional Biochemical Assays..................................................................96 
Appendix D: Additional Experimental Design................................................................98 
Appendix E: Stereologer Software Instructions.............................................................100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvii 
LIST OF ABBREVIATIONS 
6-OHDA 6-hydroxydopamine 
ATP  adenosine triphosphate 
BBB  blood brain barrier 
BDNF  brain derived neurotrophic factor 
cAMP  cyclic adenosine monophosphate 
CDNF  cerebral dopamine neurotrophic factor 
CNS  central nervous system 
CoQ10  coenzyme Q10 
DA  dopaminergic 
DAT  dopamine transporters 
DOPA  dihydroxylphenylalanine 
ETC  electron transport chain 
GDNF  glial derived neurotrophic factor 
GLF  glial derived neurotrophic factor family of ligands 
GSH  reduced glutathione 
GSSG  oxidized glutathione 
HAT  histone acetyltransferase 
HPLC  high-performance liquid chromatography 
H2O2  hydrogen peroxide 
IL-1β  interleukin-1β 
IL-6  interleukin-6 
LRRK2 Leucine-rich repeat kinase 2 
MANF  mesencephalic astrocyte-derived neurotrphic factor 
 xviii 
MPP+  1-methyl-4-phenylpyridinum 
MPTP  1-methl-4-phenyl-1,2,3,6-tetrahydropyridine 
NADH  nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
NET  norepinephrine transporters 
NGF  nerve growth factor 
NOS  nitric oxide species 
NOX1  NADPH oxidase 1 
NRC  National Research Council (Canada) 
NTF  neurotrophic factor 
OS  oxidative stress 
PARK6 PTEN-induced kinase 1 
PARK8 LRRK2 
PARK2 Parkin 
PD  Parkinson’s disease 
PET  positron emission tomography 
PINK1  PTEN-induced kinase 1 
PITX3  pituitary homeobox 3 
PQ  paraquat (1,1’-dimethyl-4,4’-bipyridium) 
PSST  NADH dehydrogenase [ubiquinone] iron-sulfur protein 7 
PTEN  Phosphatase and tensin homolog  
PTS  polyoxyethanyl α-tocopheryl sebacate acid 
ROS  reactive oxygen species 
SN  substantia nigra 
 xix 
SNpc  substantia nigra pars compacta 
SOD  superoxide dismutase 
TH  tyrosine hydroxylase 
TNF-α  tumor necrosis factor alpha 
TrkB  tyrosine-related kinase B 
VMAT  vesicular monoamine transporters 
VTA  ventral tegmental area 
WS-CoQ10 water-soluble coenzyme Q10 
 
 
 
 
 
 
 
 
 1 
CHAPTER I 
INTRODUCTION 
1.1. Parkinson’s Disease 
In 1817, James Parkinson was the first to describe one of the most common 
neurodegenerative disorders, the “shaking palsy” known today as Parkinson’s disease 
(Parkinson, (1817) 2002).  It is the second most common neurodegenerative disease, 
behind Alzheimer’s disease, and affects over 5 million people worldwide (Michael J. Fox 
Foundation for Parkinson’s Research, MichaelJFox.org). 
Parkinson’s disease (PD) is characterized by the progressive loss of dopamine 
producing neurons, primarily in the substantia nigra pars compacta (SNpc) region of the 
midbrain.  The loss of these neurons contributes to the symptoms commonly associated 
with PD: bradykinesia, resting tremors, rigidity, loss of balance, stooped posture and 
shuffling gait, which usually do not develop until more than 60% of the dopaminergic 
(DA) neurons have already been lost (Jankovic, 2008).  One of the main hallmarks of PD 
is the presence of cytoplasmic Lewy bodies, composed of α-synuclein protein aggregates 
in the surviving dopaminergic neurons (Lozano & Kalia, 2005; Wakabayashi et al., 
2007).  They can also be found in other areas of the brain such as the cortex and basal 
forebrain (Braak et al., 1995).  
Currently there are no treatments available to slow or halt the progression of PD.  
There are some drugs such as levodopa that temporarily ameliorate symptoms, but these 
drugs cannot sustain aid after long-term use.  Therefore, it is of great importance to 
develop a therapy that will help patients diagnosed with PD to live full and almost normal 
lives. 
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1.2. Synthesis, Release and Metabolism of Dopamine 
Dopamine is a neurotransmitter required for a variety of biological functions 
including: voluntary movement, motivation, behaviour and cognition, punishment and 
reward, sleep, mood, attention, working memory and learning.  It also acts as both a 
positive inotrope and chronotrope that increases heart rate by strengthening its muscular 
contractions (Howard, 2008). 
 Dopamine is classified as a catecholamine due to its derivation from the amino 
acid tyrosine.  Tyrosine is converted into L-3,4-dihydroxylphenylalanine (L-DOPA) by 
the enzyme tyrosine hydroxylase (TH) and then to dopamine by DOPA decarboxylase 
(Figure 1).  Dopamine can also be further processed into norepinephrine and epinephrine, 
Figure 1: Dopamine synthesis.  The catecholamine, dopamine, is derived from the 
amino acid tyrosine using the rate-limiting enzyme tyrosine hydroxylase and L-Dopa 
carboxylase. 
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other neurotransmitters involved with the fight-or-flight response.  The enzymes, tyrosine 
hydroxylase and DOPA decarboxylase, are found in the soma of neurons where they are 
transported to the axon to synthesize dopamine.  Once it is synthesized, transporting 
vesicles called vesicular monoamine transporters (VMAT), transport dopamine through 
the synaptic cleft to the target neuron.  The action of the neurotransmitter is terminated by 
either uptake back into nerve terminals or uptake from nearby glial cells by Na+-
dependent dopamine transporters (DAT) (Moron et al., 2002, Figure 2). 
The enzymes required to degrade dopamine into homovanillic acid are 
monoamine oxidase and catechol O-methyltransferase, which both glial cells and neurons 
possess (Dziedzicka-Wasylewska, 2004; Joh & Hwang, 1987).  Homovanillic acid is then 
excreted in urine. 
Figure 2:  Neurotransmitting dopamine.  Signally neurons from the substantia nigra 
pars compacta to the striatum transport the neurotransmitter dopamine from vesicular 
monoamine transporters to D1 receptors. 
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1.3. The Nigrostriatal Pathway 
 The majority of dopamine in the brain (80%) is produced in the substantia nigra 
and ventral tegmental area (VTA, Carlsson, 1959), and additionally by the arcuate 
nucleus of the hypothalamus.  Dopamine originating in these three regions is involved in 
four main pathways: mesocortical, mesolimbic, tuberoinfundibular and nigrostriatal 
(Figure 3).  
The nigrostriatal pathway is the pathway most associated with Parkinson’s disease 
because it is mainly involved with voluntary movement and cognitive function, both of 
which are compromised in PD due to the loss of dopaminergic neurons.  The nigrostriatal 
pathway is courses through the cortex, thalamus and basal ganglia.  The basal ganglia are 
a group of nuclei consisting of the striatum (further containing the putamen and caudate 
nucleus), the globus pallidus: pars intera and pars externa, the subthalamic nucleus and 
the substantia nigra (Figure 4). 
Figure 3: Dopaminergic pathways.  Sources and projections of three main dopamine 
pathways in the human brain. 
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 The basal ganglia circuitry is considered a neuronal loop that receives cortical 
input and transmits back to the motor cortex via the thalamus.  The neurons in the basal 
ganglia modulate their own activity in anticipation of movement, sometimes up to several 
seconds before initiation, as well as during voluntary movements (Purves et al., 2008). 
The circuitry of the basal ganglia can be further subdivided into the direct 
pathway, and indirect pathway (Figure 5).  In the direct pathway the striatum receives 
dopaminergic transmission from the substantia nigra pars compacta through the D1 
receptor; this in turn creates an inhibitory signal to the globus pallidus pars interna that 
 
 
 
 
 
 
Figure 4: Nigrostriatal pathway.  Dopamine is projected from the substantia nigra pars 
compacta to the putamen and caudate nucleus. 
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further inhibits projections to the thalamus.  This allows the thalamus to give an 
excitatory signal to the motor cortex where it can reach the muscles and initiate 
movement.  Overall, the direct pathway is excitatory and is modulated by the substantia 
nigra pars compacta and dopamine receptor, D1. 
 Alternatively, the indirect pathway involves an inhibitory projection to the 
striatum from the substantia nigra pars compacta through D2 receptors.  This inhibitory 
pathway follows the striatum to the globus pallidus pars externa to the subthalamic 
nucleus.  The subthalamic nucleus sends an excitatory signal to the globus pallidus pars 
interna that inhibits the excitatory projects of the thalamus to the cortex (Figure 5).  
Overall, the indirect pathway is inhibitory and modulated through the D2 dopamine. 
Figure 5: Basal ganglia circuitry.  Neuronal loop modulated by the substantia nigra pars 
compacta through D1 and D2 receptors leading to either the direct or indirect pathway. 
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The indirect pathway influences the direct pathway in a way that leads to opposite, 
yet synergistic effects.  Increasing levels of dopamine from the direct pathway decreases 
the sensitivity of the indirect pathway, amplifying the excitatory signal.  The opposite is 
true in situations with decreased levels of dopamine, which increases sensitivity and 
amplifies the inhibitory signal from the direct pathway.  In Parkinson’s disease, loss of 
dopamine transmission to the basal ganglia is high, contributing to the characteristic 
symptoms, such as difficulty initiating movement.  Post-mortem studies of those 
diagnosed with PD have shown a decrease of dopamine in the substantia nigra, globus 
pallidus, putamen and caudate nucleus, as well as a decrease in dopamingeric neuronal 
fibres in the striatum (Hornykiewicz, 2006). 
 
1.4. Etiology of Parkinson’s Disease 
The average age of onset of Parkinson’s disease is 60 years; however, the 
occurrence of early onset is on the rise and prevalent in approximately 4% of people 
diagnosed with PD (Parkinson’s Disease Foundation, PDF.org).  Interestingly, males are 
2.5 times more likely to develop this disease than women.  This is believed to be due to 
the neuroprotective effects of estrogen in the SN from higher levels of glutaredoxin that is 
expressed through estrogen receptor signaling (Kenchappa et al., 2004). 
The cause of PD is unknown, but it is believed that both genetic and 
environmental factors, especially in combination contribute to the development of the 
disease (Terzioglu & Galter, 2008).  A study using monozygotic and dizygotic twins in 
the 1990s determined that PD is not hereditary, although early onset PD has been linked 
to genetic factors (Tanner et al., 1999).   The natural aging process is another factor in 
developing PD due to the fact that most brain neurons are post-mitotic, and oxidative 
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stress increases with age (Beal, 2003; Bishop et al., 2010; Hindle, 2010).  Normal brains 
lose 4.7% to 6% of neurons between the ages of 50 and 90 (Gibb & Lees, 1991).  Since 
the average life expectancy is increasing, so is the prevalence of PD. 
Sporadic incidences of PD account for more than 95% of PD cases and may be 
influenced by environmental factors, such as exposure to herbicides and pesticides.  
People who work in agriculture and are exposed to these toxins have a 2.5 times increased 
risk of developing PD (Tanner et al., 2011).  On the other hand, genetic factors attribute 
to less than 5% of incidences of PD.  To date, several genes that acquire mutations have 
been linked to the disease: PARK2 (Parkin), PARK6 (PTEN-induced kinase 1), α-
synuclein, leucine-rich repeat kinase 2 (LRRK2) and DJ-1.  What is most interesting is 
that several of these genes affect mitochondrial function, whose involvement in 
Parkinson’s disease will be described in detail (Abou-Sleiman, Muquit & Wood, 2006). 
Currently, there are no genetic or animal models for PD that can replicate all the 
key features of the disease: motor deficits, dopaminergic neuronal cell loss in the SN, loss 
of dopaminergic fibers in the striatum and the presence of Lewy bodies.  In fact, most 
mutations associated with PD simply increase predisposition to the disease and do not 
lead to the development of the symptoms directly.   Therefore, genetic models are better 
suited for increasing susceptibility to PD pathology through means of inducing oxidative 
stress, protein aggregation, and interfering with dopamine neurotransmission.  However, 
the models that have been established greatly contribute to our understanding of the 
disease and enhance the opportunity of discovering a cure. 
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1.5. Genetic Causes of Parkinson’s Disease 
 There have been many discoveries of genes associated with or leading to 
Parkinson’s disease.  The following table is a summary of the genes discovered to date 
(Table 1). 
 
Table 1: Parkinsonism genetics.  Genes leading to Parkinsonism and their pathology 
(modified from Hardy, 2010). 
 
Locus Genes Clinical Features Pathology 
Dominant 
PARK1/4 α-Synuclein Typical PD but can sometimes 
have a dementia presentation 
Lewy bodies 
PARK8 LRRK2 Typical PD Usually Lewy bodies: 
sometime tangles, 
sometimes neither 
Recessive 
PARK2 Parkin Very slowly progressive early 
onset disease usually with 
sleep benefit 
Usually not Lewy bodies 
PARK6 PINK1 Usually very slowly 
progressive early onset disease 
usually with sleep benefit 
One case with Lewy 
bodies 
PARK7 DJ-1 Little data, but seems similar 
to parkin 
Not known 
PARK9 ATP13A2 Aggressive and complex 
parkinsonism with many 
additional features 
Not known 
PARK14 PLA2G6 Aggressive and complex 
Parkinsonism with many 
additional features 
Lewy bodies 
 
1.5.1. Alpha-synuclein 
 Alpha-synuclein is a protein expressed in the central nervous system whose actual 
function is not clearly understood, but may be linked to coordinating nuclear and synaptic 
events.  In regards to Parkinson’s disease, α-synuclein is the main protein that aggregates 
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in Lewy bodies in both sporadic and while rare, familial incidences of PD, due to genetic 
mutations (Stoica et al., 2012).  In a spontaneously inherited autosomal recessive rat 
model of Parkinson’s disease, it was discovered that α-synuclein was largely increased in 
the midbrain along with decreased levels of DA in the striatum.  The high accumulation 
of α-synuclein in the midbrain is believed to lead to the deterioration of nerve terminals, 
synapses and dendrites that in turn debilitate the transmission of DA (Stoica et al., 2012).  
It is still unclear whether α-synuclein is neuroprotective or neurotoxic under certain 
circumstances, ranging from environmental toxic exposure to genetic mutations. 
 
1.5.2. PARK Gene Family  
Mutations in the PARK8 gene coding for the leucine-rich repeat kinase 2 protein 
(LRRK2), causes familial PD (Zimpritch et al., 2004).  There have been up to six 
mutations detected in this gene that can lead to Parkinsonian symptoms including 
dopaminergic cell death, Lewy bodies, and dementia.  The most frequently occurring 
G2019S mutation is linked to both sporadic and familial PD (Gilks et al., 2005).  It has 
been shown to cause decreased striatal dopamine transmission, a loss of dopaminergic 
neurons, and abnormalities in both mitochondrial function and autophagy in a transgenic 
mouse model (Li X et al., 2010; Ramonet et al., 2011).  While the G2019S mutation does 
not show any motor deficits, the R1441G mutation leads to reduced mobility (comparable 
to bradykinesia), as well as tau protein aggregation in transgenic (BAC) mice (Li Y et al., 
2009). 
 Parkin is an ubiquitin protein ligase expressed by the PARK2 gene that is most 
widely known, when mutated, to cause early onset Parkinson’s disease.  Those affected 
with a Parkin mutation usually develop the symptoms of PD, with the exception of Lewy 
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body formation, before the age of 40 (early onset) (Poorkaj et al., 2005).  Staggering 
statistics estimate that almost 50% of familial PD and 18% of sporadic PD are due to 
Parkin mutations (Clark et al., 2006). 
PTEN induced kinase 1 (PINK1) protein is expressed by the PARK6 gene whose 
mutations cause autosomal recessive and early onset PD (Valente et al., 2004).  PINK1 is 
found in the mitochondria and associated with phosphorylation involved in 
morphogenesis and fission, as well as mitochondrial autophagy (Yan et al., 2012).  In cell 
culture models, knockdown of PINK1 causes mitochondrial and proteasome dysfunction 
and alpha-synuclein aggregation (Liu et al., 2009). 
The PARK7 gene mutation corresponds to DJ-1 protein misfolding or loss of 
function at its highly conserved cysteine residue (L166P) (Wilson et al., 2003).  DJ-1 is 
found in the cytoplasm of cells, and in the event of oxidative stress, is translocated to the 
mitochondria (Canet-Aviles et al., 2004).  There it can perform anti-oxidative activities 
by oxidizing itself; however, when the L166P cysteine is mutated it cannot homodimerize 
and loses its function (Takahashi-Niki et al., 2004).  The protein is known to help reduce 
oxidative stress by scavenging H2O2, inhibiting α-synuclein aggregation and regulating 
other pro-survival genes (Junn et al., 2009).  The DJ-1 mutation is associated with early 
onset PD; however it is a rare occurance and does not show loss of dopaminergic neurons 
on its own (Bonifati et al., 2003; Yamaguchi & Shen, 2007).  Current studies are using 
DJ-1 knockout animals combined with environmental toxins, such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Kim et al., 2005), and paraquat to induce 
Parkinsonism symptoms is a more realistic model of PD.  DJ-1 deficient mice challenged 
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with MPTP have an increase in both oxidative stress and dopaminergic neuronal cell 
death (Bohlen & HO, 2005).  
 
1.6. Toxin and Environmental Causes of Parkinson’s Disease 
1.6.1. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
 In vivo models of idiopathic PD have always been difficult to establish.  However, 
in the 1980s a major breakthrough was made when a group of heroine addicts displayed 
symptoms of PD at a young age.  It was discovered that a by-product, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP, Figure 6) of the synthetic heroine they were injecting 
intravenously, was the cause of their PD-like symptoms.  Post mortem studies revealed 
these addicts had a selective loss of SN neurons and Lewy body inclusions (Langston, 
Figure 6: Neurotoxins.  Structures of neurotoxins: oxydopamine, rotenone, MPTP, 
MPP+ and paraquat.  All can be involved in the pathogenesis of Parkinson’s disease. 
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1983).  This compound provided the first model to be used in PD research and was a 
gateway to discovering similar toxins that could potentially contribute to PD pathology. 
MPTP is a lipophilic, non-toxic compound that can easily cross the blood-brain 
barrier.  It becomes toxic to neurons when metabolized by astrocytes into 1-methyl-4-
phenylpyridinium (MPP+, Figure 7) by monoamine oxidase B.  MPP+ enters neurons by 
DAT, where it accumulates in the DA neurons and inhibits complex I of the 
mitochondrial electron transport chain (ETC).  This disrupts mitochondrial function and 
leads to an increase in ROS, lipid oxidation and protein oxidation in rodent models 
(Smeyne & Jackson-Lewis, 2005).  MPP+ can also inhibit complex III and IV further 
decreasing adenosine triphosphate (ATP) production and increasing oxidative stress 
(Mizuno et al., 1988).  When MPTP is converted to MPP+ in the astrocytes, it stimulates 
TNF-α, IL-1B, and IL-6 expression leading to inflammation and neuronal cell death 
(Teismann et al., 2003; Youdim et al., 2002). 
Increased doses of MPTP in mice showed a progressive loss of DA neurons in the 
SN as well as decreased DA terminals in the striatum and clear motor deficits (Goldberg 
et al., 2011).  These deficits have also been shown in a variety of animal models 
including rodents, cats, mini-pigs and non-human primates (Jenner, 2003; Wichmann & 
DeLong, 2003; Terzioglu & Galter, 2008).  
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1.6.2. Paraquat 
The environmental toxin, 1,1′-dimethyl-4,4′-bipyridium (paraquat, PQ) is one of 
the most widely used herbicides in the world (Dinis-Oliveira et al., 2008; Frabotta, 2009).  
It is structurally similar to the neurotoxin MPP+ with the addition of a methylpyridinium 
group (Figure 6). Unlike MPP+, PQ does not use dopamine transporters to enter DA 
neurons; instead it enters via diffusion and is then taken up by the mitochondria through 
neutral amino acid transporters (Shimizu et al., 2001; McCormack et al., 2003). 
Exposure to PQ causes superoxide production that takes place in the 
mitochondrial matrix and leads to mitochondrial oxidative damage, lipid oxidation, and 
protein peroxidation.  There is controversy whether paraquat is involved directly at 
complex I of the mitochondrial ETC or by Bak-dependent mechanisms.  If at complex I, 
DAT 
Figure 7: MPTP metabolism.  MPTP is first converted to MPDP (1-methyl-4-phenyl-
2,3,-dihydropyridinium) by monoamine oxidase, then spontaneously to MPP+ in 
astrocytes.  MPP+ enters dopaminergic neurons via DAT and increases oxidative stress 
by blocking complex I of the ETC. 
MPDP 
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PQ2+ is reduced by a single electron from NADH and forms the radical cation (PQ⋅+) 
(Cocheme & Murphy, 2008).  The radical quickly reacts with oxygen to create a 
superoxide radical (O2⋅-), which can then be converted to hydrogen peroxide (H2O2) by 
superoxide dismutase leading to oxidative stress (Berry et al., 2010, Figure 8).  The other 
possibility is that PQ stimulates high levels of pro-apoptotic Bcl-2 family members 
through oxidative stress, which induce the intrinsic apoptosis pathway (Qingyan et al., 
2008).  Nonetheless, in animal models, exposure to PQ induces PD-like symptoms 
including specific loss of TH positive neurons in the SN (Betarbet et al., 2002; Terzioglu 
& Galter, 2008; McCormack et al., 2002; Ossowska, 2006). 
 Studies from Taiwan and East Texas found that exposure to paraquat increased the 
risk of developing PD, especially with more than 20 years of exposure (Liou et al., 1997; 
Figure 8: Reduction-oxidation cycling of paraquat.  Paraquat blocks complex I of the 
ETC by preventing electron transfer from NADH.  Instead, PQ receives the electron and 
becomes a radical that reacts with oxygen to form a superoxide. 
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Dhillon et al., 2008).  Another study found exposure at younger ages increased the risk as 
well as the early onset of acquiring PD (Costello et al., 2009).  Even more recently, 
studies show evidence that paraquat and rotenone are linked to PD.  Out of 31 pesticides 
that were evaluated, rotenone was considered to have the strongest correlation to PD as a 
complex I inhibitor and paraquat had the strongest association with PD as an oxidative 
stressor (Tanner et al., 2011). 
Paraquat has also been associated with histone acetylation, specifically of H3 in 
cell culture models.  The inhibition of histone acytltransferase (HAT) activity (via 
anacardic acid) protects against apoptotic dopaminergic cell death.  It reduces histone 
deacetylase activity and may be a key player in the epigenetic changes of PD (Song et al., 
2011).  The mechanism of paraquat toxicity has shown to include the up-regulation of a 
superoxide-generating enzyme, NADPH oxidase 1 (Nox1).  Increased expression of Nox1 
by paraquat induces oxidative stress and leads to dopaminergic neuronal loss (Cristovao 
et al., 2009). 
 
1.6.3. Rotenone 
Rotenone (Figure 6) is a ketone found in the roots and stems of the Lonchocarpus 
species of tropical plants and was initially used as a fish poison by native Indians 
(Uversky, 2004).  Since rotenone is lipophilic, it can cross the blood brain barrier (BBB) 
and easily enter the mitochondrial membrane.  It has a high affinity for the PSST subunit 
of complex I (NADH:ubiquinone reductase) of the ETC (Nicolaou et al., 2000; Schuler & 
Casida, 2001).  By inhibiting complex I, rotenone increases oxidative stress by ROS 
production, protein oxidation, and mitochondrial dysfunction (Kushnareva et al., 2002; 
Sherer 2003b). 
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 In nature, rotenone can break down very quickly in sunlight, water and soil, with a 
half-life ranging between 1 to 3 days (Pesticides News, 2001).  Therefore, exposure to 
rotenone is not a very likely cause of PD.  Conversely, a recent study found that exposure 
to rotenone was associated to an increased risk of developing PD (Tanner et al., 2011). 
Despite this, rotenone is a good model for studying PD in both cell culture and animal 
models.  Rotenone administered intrajugularly, subcutaneously, intraperitoneally by 
infusion or chronically, induces a loss of DA neurons (Betarbet, 2000; Sherer, 2003c; 
Alam & Schmidt, 2002).  Since rotenone does not enter DA neurons through DAT like 
MPP+, it penetrates all mitochondria throughout the brain; however, it shows a specific 
loss of DA neurons in the SN.  Rotenone also induces cytoplasmic inclusions much like 
Lewy bodies that contain α-synuclein (Betarbet, 2000; Sherer, 2003).   Furthermore, 
rotenone administration gives rise to behavioural deficits similar to PD symptoms such as 
bradykinesia, rigidity and postural problems (Betarbet et al., 2000; Sherer et al., 2003c).  
The downside to this model is that the severity of neuronal damage is highly variable; 
some motor deficits could be due to other factors such as general health problems and 
some studies have shown non-DA neuron striatal damage (Hoglinger et al., 2003). 
 
1.6.4. Oxidopamine/6-hydroxydopamine (6-OHDA) 
 The most widely used and reproducible model of PD uses the neurotoxin 6-
hydroxydopamine, a hydroxylated derivative of dopamine (Figure 6).  Given that it 
cannot cross the blood-brain barrier, it must be injected directly into the brain, usually 
into the striatum or SN region.  In rodents, dopamine transporters and norepinephrine 
transporters (NET) carry the toxin to neurons, where it induces reactive oxygen species 
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(ROS) leading to the death of DA neurons (Bove et al., 2005).  However, it cannot mimic 
the progressive loss of DA neurons (Mercanti et al., 2012).  What is novel about this 
method is that the animal can provide its own control by injecting unilaterally.  DA loss 
can be seen only in the ipsilateral hemisphere where the injection was given; the other 
hemisphere remains untouched (Blandini et al., 2008, Figure 9). 
1.7. Mechanism of Neurodegeneration 
Whether the source is genetic, environmental or a combination of the two, the 
pathogenesis of Parkinson’s disease has boiled down to a few common mechanisms 
involving mitochondrial dysfunction leading to oxidative stress and inflammation. 
Figure 9: Tyrosine hydroxylase positive neurons following oxidopamine injections. 
When oxidopamine is injected into the brain, a loss of SN and VTA dopaminergic 
neurons (darkly coloured) can be seen on the same side as the injection, whereas the other 
side of the brain is completely unaffected (Costa et al., 2012). 
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1.7.1. Oxidative Stress Leading to Mitochondrial Dysfunction 
Oxidative stress exists when there is an imbalance of reactive oxygen species 
production and antioxidant activity.  Neurons are highly sensitive to oxidative stress 
because they depend almost solely on oxidative phosphorylation for energy.   
Mitochondria, where this oxidative phosphorylation takes place, are already under high 
levels of oxidative stress and therefore any increase in internal or external ROS tips the 
balance and leads to mitochondria becoming dysfunctional.   This in turn produces more 
ROS leading to a damaging and unending cycle (Figure 10). 
To combat ROS production, mitochondria use manganese superoxide dismutase, 
which converts superoxide radicals to hydrogen peroxide.  The hydrogen peroxide is then 
further converted by peroxidases into water (Harrison & Hollensworth, 2005).  However, 
in situations with high levels of oxidative stress, these enzymes are sometimes 
inadequate.  Likewise, as we age, we become more susceptible to oxidative stress. 
Figure 10: Mitochondria under oxidative stress.  Unfavorable conditions in the 
mitochondria due to environmental toxin exposure lead to a cycle of ROS production. 
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1.7.2. Oxidative Stress in Parkinson’s disease 
Susceptibility to this disease can be due to genetics, environmental toxins 
(including most pesticides and herbicides) or a combination of the two, which can cause 
mitochondrial damage, eventually leading to oxidative stress. 
Generation of reactive oxygen species at complex I, coined “complex I 
syndrome,” in the ETC has been linked to age-associated modifications in the central 
nervous system (Harrison et al., 2005; Nobre et al., 2009).  Increased levels of oxidized 
glutathione (GSSG) with a correlated decrease in reduced glutathione (GSH), oxidized 
protein, and increased lipid peroxidation are all common ways of measuring oxidative 
stress and the extent of damage caused by it.  Lipid peroxidation causes a collapse of 
plasma and mitochondrial membranes, releasing cytochrome c and inducing apoptosis.  
The brain is most affected by lipid peroxidation because of its high oxidizable lipid and 
metal content in comparison with other tissue (Nobre et al., 2009).  Chronic exposure to 
hydrogen peroxide has been shown to have a protective role by inducing up regulation of 
antioxidant enzymes such as catalase and superoxide dismutase (Gomez-Cabrera et al., 
2008).  A study that measured oxidized CoQ10 in the cerebrospinal fluid of untreated PD 
patients discovered that oxidative damage to mitochondria and mitochondrial DNA may 
be involved in the pathogenesis of PD (Isobe et al., 2010). 
 
1.7.3. Neuroinflammation 
Neuroinflammation in the midbrain occurs several years before the onset of PD 
symptoms (Zinger, 2011).  Microglia are modified immune cells involved in the 
neuroinflammatory process.  These microglia are microphages recruited by pro-
inflammatory messengers, cytokines, and chemokines to the area of damaged brain tissue.  
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The main job of microglia is to phagocytose damaged neurons, that in turn release toxic 
materials and further recruit pro-inflammatory molecules and a damaging cycle begins.  
As well, microglia themselves can release pro-inflammatory molecules such as, TNF-α, 
ROS, and NOS (Gehrmann, 1995).  In healthy brains, there is a balance between the 
protective and inflammatory responses, but similar to oxidative stress, any extra influence 
tips the balance. 
Out of all the other brain areas, the substantia nigra contains the highest amount of 
microglia (McGeer, 1988).  Microglia are believed to play a significant role in the 
initiation and progression of PD.  An increase in activated microglia in the midbrain has 
been shown in positron emission tomography (PET) scans of PD patients, especially in 
the early stages of the disease (Ouchi, 2005).  Other post-mortem studies have found that 
an increase in activated microglia was initiated by up-regulation of α-synuclein.  The 
microglia activation was found to be early in the diagnosis and lasted throughout the 
disease (Sanchez-Guajardo, 2010). 
 
1.8. Antioxidants as Possible Therapeutic Agents for Parkinson’s Disease 
Antioxidants are reducing agents that inhibit the oxidation of molecules into 
becoming free radicals.  The role of antioxidants in maintaining redox balance is well 
known and although they are able to alleviate the effects of oxidative stress, nothing has 
been discovered that can stop the neurodegeneration process associated with oxidative 
stress. 
Recent studies for the treatment of PD have been directed towards anti-oxidative 
agents that target and stabilize the mitochondria (Muller et al., 2010).  Some of these 
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treatments include: glutathione, curcumin, Vitamin E, Vitamin C, Vitamin A, 
peroxidases, ubiquinol (coenzyme Q, Table 2).  Some of these will be explained in 
greater detail as they pertain to the therapeutic treatment of PD in a rat model. 
 
1.8.1. Vitamin E 
Tocopherol (Vitamin E) is a fat-soluble alcohol needed for the stabilization of cell 
membranes.  It is found in such foods as egg yolks, and vegetables and can also be taken 
as a health supplement, where it has been found to be safe at high doses (Hathcock, 
Table 2: Effects of antioxidants on neurodegenerative diseases.  Common antioxidant 
compounds with antioxidative properties have shown to play a role in reducing oxidative 
stress in Parkinson’s disease, Alzheimer’s disease and stroke (Facecchia et al., 2011). 
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2005).  Vitamin E can easily cross the BBB and acts as an antioxidant for lipid radicals 
produced from lipid peroxidation (Halliwell & Gutteridge, 1989).  It can also aid 
glutathione in reducing lipid peroxidation and oxidative stress by maintaining its non-
radical antioxidative characteristics through reduction (Van Haaften et al., 2003; Gupta et 
al., 2011, Figure 11).   Studies have shown that vitamin E is effective in decreasing 
oxidative stress, increasing life span, and improving brain mitochondria efficiency, 
specifically in the hippocampus and frontal cortex of aging rodent brains (Vatassery et 
al., 2004; Navarro et al., 2010). 
 
1.8.2. Coenzyme Q10 (CoQ10) 
Coenzyme Q10 is an important hydrophobic compound found consistently 
throughout all membranes, especially in the mitochondrial membrane.  It is the only 
endogenously biosynthesized lipid-soluble antioxidant, important for maintaining both 
lipid and mitochondrial membranes (Noack et al., 1994; Forsmark-Andree et al., 1997; 
Bentinger et al., 2007).  CoQ10 has four major functions: redox carrier, antioxidant, 
uncoupling protein activator and has influence on the permeability transition pore.  
Figure 11: GSH and Vitamin E interaction.  Vitamin E (α-tocopherol) reduces lipid 
peroxidation and in turn Vitamin E radicals are restored to their reduced state by GSH 
(Van Haaften et al., 2003). 
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The primary role of CoQ10 in regards to redox reactions involving ATP production 
is to shuttle electrons from complex I and II to complex III of the mitochondrial ETC.  It 
does this by binding to complex I at the iron center containing PSST subunit site where it 
is reduced from its fully oxidized ubiquinone form to its ubisemiquinone semiquinone 
form, which it can then accept another electron to become fully reduced ubiquinol 
(Schuler et al., 1999; Bentinger et al., 2007, Figure 12). 
As mentioned previously, complex I of the ETC is a major source of ROS 
(Murphy, 2009).  Since CoQ10 is found in high concentrations in the mitochondrial 
membrane around complex I, it is a good candidate for treatment of neurodegerative 
Figure 12: Involvement of CoQ10 in the electron transport chain.  CoQ10 shuttles 
electrons from complex I, and complex II to complex III of the electron transport chain 
(Liu & Schubert, 2009). 
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diseases that are the result of mitochondrial oxidative stress.  However, due to its highly 
hydrophobic nature, CoQ10 cannot be used in cell culture media.  Therefore, very little 
has been published regarding in vitro CoQ10 studies. 
In vivo studies on the other hand have shown that CoQ10 can provide 
neuroprotection to DA neurons in the SN, striatal dopamine terminals, DA axons and 
reduce α-synuclein aggregation in an MPTP mouse model, including chronically 
administered MPTP and aged mice (Beal et al., 1998; Cleren et al., 2008).  This has also 
been shown in primates (Horvath et al., 2003).  CoQ10 unlike other antioxidants can 
inhibit the initiation of protein and lipid oxidation instead of combating it (Bentinger et 
al., 2007). 
 
1.8.3. Water-soluble Coenzyme Q10 
Due to the lack of in vitro studies, and low bioavailability associated with CoQ10, 
a new water-soluble formulation was developed (NRC, Ottawa).  CoQ10, α-tocopherol, 
and polyethyleneglycol were combined to form a nanomicelle in aqueous solutions 
(Figure 13).   
Firstly, polyoxyethanyl α-tocopheryl sebacate acid (PTS) is synthesized by 
conjugating polyethylene glycol 600 to α-tocopherol via bi-functional sebacic acid 
(Sigma-Aldrich, St. Louis, MO) as previously described (Borowy-Borowski et al., 2004).  
Next, CoQ10 is dissolved in a solution with PTS forming a non-covalent complex and 
then a ‘nanomicelle.’  The important 2:1 ratio of PTS to CoQ10 is imperative to its 
function (Sikorska et al. 2003, Borowy-Borowski et al. 2004).  After oral administration, 
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it is cleaved by non-specific esterases and PTS is hydrolyzed to Vitamin E.  This allows 
for aqueous delivery of CoQ10 and Vitamin E.  
This water-soluble formulation of CoQ10 (WS-CoQ10) protected human neuronal 
cells against oxidative stress-induced cell death in in vitro human teratocarcinoma and 
human neuroblastoma cell culture models (Sandhu et al., 2003; McCarthy et al., 2004; 
Somayajulu-Nitu et al., 2005).  Furthermore, it has been shown that WS-CoQ10 not only 
decreased oxidative stress, but stabilized mitochondria and prevented Bax-induced 
mitochondrial permeabilization (Naderi et al., 2006).  Most importantly, in a recent study 
with a paraquat-induced Parkinson’s disease rat model, WS-CoQ10 was shown to be 
 
 
 
 
 
 
 
Figure 13: Water-soluble formulation of coenzyme Q10. Nanomicelles form around 
hydrophobic CoQ10 in solution to allow for aqueous delivery of the compound 
(Zymes LLC).   
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effective in preventing DA neuronal loss in the SN and amelioration of PD-related 
behvioural symptoms in rats (Somayajulu et al., 2009).   
 
1.9. Role of Glial Cells in Preventing Neuronal Cell Death 
Glial cells are non-neuronal cells that provide support to neurons.  There are four 
different types of glial cells: oligodendrocytes, ependymal, microglia and astrocytes.  
Oligodendrocytes supply the structural support of the myelin sheath that covers and 
protects neuronal projections.  Ependymal cells compartmentalize membranes and create 
barriers.  Physical aid is given by microglia that act as phagocytes for damaged neurons. 
Astrocytes provide biochemical support to neurons by transporting nutrients from the 
blood to neurons, maintaining homeostasis by absorbing excess potassium and 
neurotransmitters, and by secreting neurotrophic factors needed for growth and sustaining 
neurons (Purves et al., 2008).   
 
1.9.1. Neurotrophic Factors 
The word ‘trophic’ comes from the Greek trophe for “nourishment.”  There are 
four main families of neurotrophic factors: neurotrophins, glial derived neurotrophic 
factors, neurotrophic cytokines, and cerebral dopamine neurotrophic 
factors/mesencephalic astrocyte-derived neurotrophic factors.   
In the central nervous system (CNS), neurotrophic factors (NTFs) are secreted by 
astrocytes, where they control differentiation, growth, plasticity and survival of neurons 
(Purves et al., 2008).  Certain neurotrophins provide support to specific types of neurons.  
Highly selective action is based on localization and expression of the receptor on the 
target neuron.  For example, brain derived neurotrophic factor (BDNF) is expressed only 
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in the CNS and has high affinity to tyrosine-related kinase B (TrkB) receptors.  These 
receptors elicit either pro-survival or pro-apoptotic actions depending on the cascade that 
follows receptor binding (Figure 14).	  	  
Glial derived neurotrophic factor (GDNF) belongs to the pro-survival family of 
ligands (GLF) for dopaminergic neurons in vitro (Lin et al., 1993) and has shown to 
trigger synaptogenesis in hippocampal neurons (Ledda et al., 2007).  Removing GDNF 
expression exhibited DA neuronal loss in both the SN and VTA as well as a loss of 
striatal DA terminals (Pascual et al., 2008; Kramer et al., 2007).  Other in vitro studies 
have shown that the mechanism of GDNF protection may be promoting survival by 
inhibiting death receptor and caspase-dependent pathways, without mitochondrial 
involvement (Yu et al., 2008).  GDNF has also been found to inhibit microglia activation, 
decreasing the inflammatory response associated with neurodegeneration in vitro (Xing et 
Figure 14: Neurotrophin receptors.  BDNF binds to TrkB receptors that encourage cell 
survival. 
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al., 2010).  In vivo studies with MPTP treated mice show that GDNF protects DA neurons 
in the SN, striatal dopamine and fibers (Schober et al., 2007). 
In new research, clinical trials administering GDNF to PD patients have been 
conducted, but were stopped due to uninspiring results and suboptimal delivery of GDNF 
to the brain (Lang et al., 2006).  Two new DA neuron NTF homologs have been recently 
discovered: cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-
derived neurotrophic factor (MANF) (Lindholm et al., 2007; Petrova et al., 2003).  
However, not much is known in terms of signaling cascades for neuroprotection 
mechanisms as of yet.  NTFs have also been studied in vivo, but they do not cross the 
BBB and must be directly injected into brain tissue. 
 
1.10. Objectives 
1. Assess the toxicity and progressive loss of dopaminergic neurons following 
paraquat injections. 
2. Quantify the bioavailability of CoQ10 post-treatment. 
3. Evaluate the efficacy of neuroprotection by post-injection feeding (therapeutic 
treatment) of WS-CoQ10. 
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CHAPTER II 
METHODS 
2.1. Animals and Animal Care 
Long-Evans Hooded male rats (3 months old) were purchased from Charles River 
Breeding Farms in St. Constant, Quebec.  Upon arrival, animals were handled everyday 
for one week prior to any behavioural or biochemical experimentation and their ears were 
punched for identification.  Rats were housed in group cages (3-4 rats per cage) with the 
room temperature maintained at 20oC.  Due to their nocturnal nature, rats were put on a 
reversed 12-hour light: 12-hour dark cycle to ensure animals were awake during 
behavioural testing during the day. 
All animal care, treatments, and procedures were approved by the University of 
Windsor Animal Care Committee (AUPP#10-15) in accordance with the Canadian 
Council for Animal Care guidelines. 
 
2.2. Behavioural Assessment 
2.2.1. Pole Test 
 The pole test was used to assess the agility and locomotion of the treated rats.  A 
meter tall pole was covered in burlap and positioned in a bin filled with bedding.  
Animals were put on the bedding for 2 minutes to become acclimatized and then put at 
the top of the pole.  If the rat did not move, it was taken off the pole after 3 minutes.  A 
video was recorded and the time it took for the rat to climb down the pole was calculated, 
as well as if the animal fell off or not.  This test was conducted once a day for three days 
only after injections. 
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2.2.2. Turn Around Test 
 The turn around test was used to determine the speed and agility of the animals 
after treatment.  Rats were placed upside down at the bottom of a metal lattice six-foot 
climbing wall, with a platform on top and gap at the bottom.  Animals were video taped 
and timed to evaluate how long it took each rat to reach the top platform.  They were 
tested once before injections for baseline times, once during injection and once after 
injections. 
 
2.3. Experimental Design 
2.3.1. Experiment I: Assessment of Paraquat Toxicity Over Time  
To determine if paraquat induces dopaminergic neuronal loss over time 
(progressively), the toxicity of paraquat was evaluated.  This experiment included twelve 
rats, each receiving a total of five intra-peritoneal injections, once every five days.  
Control rats received injections of phosphate buffered saline (PBS, 10 mg/kg) [8 g NaCl, 
0.2 g KCl, 2.68 g Na2HPO4•7H2O and 0.24 g KH2PO4 in 800 mL of dH2O, pH = 7.6] and 
normal drinking water throughout. Experimental rats received 10 mg/kg injections of 
paraquat (methyl viologen, Sigma-Aldrich, Cat. No. 856177) solution dissolved in PBS 
(10 mg/mL) and normal drinking water throughout.  The animals were then sacrificed 48 
hours, 2 weeks and 1 month after the last injection (Table 3, Figure 15).  One rat from 
each group was sent to NRC in Ottawa for HPLC analysis of paraquat levels in the brain, 
liver, and blood plasma.  The remaining rats from each group were used for tyrosine 
hydroxylase immunohistochemistry, and stereologer neuronal cell counting.  No 
biochemical assays were conducted and no behavioural experiments were conducted. 
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Injection Treatment Number of rats Sacrificed  (post-injections) 
Saline Water 3 48h/2wk/1mo 
Paraquat Water 3 48 hours 
Paraquat Water 3 2 weeks 
Paraquat Water 3 1 month 
2.3.2. Experiment II: Bioavailability and Pharmacokinetics of WS-CoQ10 
 To assess the bioavailability of WS-CoQ10, levels of CoQ10 were measured by 
high performance liquid chromatography (HPLC). Twenty-seven rats were divided into 
two main groups, those that would receive a low concentration dose (50 µg/mL) and 
those that would receive a high concentration dose (100 µg/mL) of WS-CoQ10 in their 
drinking water.  Sugar was also added to the drinking water to encourage consumption 
(37.5 g/L).  Animals were deprived of water for 23 hours and subsequently given one 
hour of normal water (control rats) or water supplemented with WS-CoQ10 (experimental 
Table 3:  Groups for Experiment I: Assessment of paraquat toxicity over time. 
Rat groupings based on injections and duration of time after last injection for sacrifice. 
Figure 15: Timeline for Experiment I: Assessment of paraquat toxicity over time. 
 
(1 every 5 days) 
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rats) in a low or high dose.  Rats were caged individually for their hour of drinking and 
levels consumed were measured.  Animals were sacrificed 1, 3 and 6 hours after their 
hour of drinking (Table 4, Figure 16).  Rats were perfused with Tyrode’s buffer and brain, 
blood, liver, kidney and heart samples were snap frozen and sent to NRC in Ottawa for 
HPLC analysis.  No behavioural experiments were conducted. 
 
Table 4: Groups for Experiment II: Bioavailability and pharmacokinetics of WS-
CoQ10.  Rat groupings based on treatment concentration and time sacrificed after WS-
CoQ10 consumption. 
Treatment 
Sacrificed (post-drinking) 
1 hour 3 hours 6 hours 
Water 1 rat 1 rat 1 rat 
50 ug/mL WS-CoQ10 5 rats 5 rats 5 rats 
100 ug/mL WS-CoQ10 3 rats 3 rats 3 rats 
 
 
Figure 16: Timeline for Experiment II: Bioavailability and pharmacokinetics of WS-
CoQ10. 
 
2.3.3. Experiment III: Assessment of Intravenous WS-CoQ10 Delivery 
 To see how quickly WS-CoQ10 is absorbed and metabolized, it was delivered 
straight into the blood stream.  Three rats were anesthetized and each received 5mg of 
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WS-CoQ10 [50mg/mL stock, 1:1 PBS dilution, 200 µL injected] injected intravenously 
through the tail vein.  Animals were then sacrificed and perfused with Tyrode’s buffer 
three hours after injections.  Blood, brain, liver, kidney and heart samples were snap 
frozen and sent to NRC in Ottawa for HPLC analysis.  No behavioural experiments were 
conducted. 
 
2.3.4. Experiment IV: Assessment of WS-CoQ10 as a Therapeutic Treatment of PD 
 Since Parkinson’s disease is diagnosed in patients after more than 50% of their 
dopaminergic neurons are lost, it is important to assess the protective effects of WS-
CoQ10 as a therapeutic treatment.  Twelve naïve rats were divided into three groups: a) 
control saline-injected rats given regular drinking water throughout, b) paraquat-injected 
rats given regular drinking water throughout, and c) paraquat-injected rats given drinking 
water supplemented with WS-CoQ10 (50 µg/mL, Table 5).   Animals were given one 
injection every five days for a total of five injections.  Twenty-four hours after the last 
injection, animals were given their normal or supplemented water ad libitum, in group 
cages for three weeks (Figure 17). 
Behavioural assessments on the rotorod, horizontal ladder, turnaround, and object 
recognition were conducted before, during, and after treatment.  Sacrifices took place 
three weeks after last injection.  This experiment was repeated with the same number of 
rats, groupings, injections, water supplementation and behavioural evaluations. 
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Table 5: Groups for Experiment IV: Assessment of WS-CoQ10 as a Therapeutic 
Treatment of PD. Rat groupings based on type of injection and type of treatment. 
Injection Treatment Number of Rats 
Saline Water 6 
Paraquat Water 7 
Paraquat WS-CoQ10 12 
 
 
Figure 17: Timeline for Experiment IV: Assessment of WS-CoQ10 as a Therapeutic 
Treatment of PD. 
 
2.4. Dissections 
2.4.1. General Supplies 
 General supplies needed for dissections include: paper towels, straight/sharp 
Deaver scissors, “mouse teeth” tissue forceps (for holding onto fur), thumb/serrated 
dressing forceps (for holding the heart), half curved iris tissue forceps (for easy brain 
collection), flat tipped forceps (for removing organs) and long serrated dressing forceps 
(for holding back rib cage) were all purchased from the Chemical Control Centre or the 
Biology stockroom, guillotine, pliers (for removing rat skull) purchased from Canadian 
Tire, ethanol in squirt bottle, black dissection paint tray (Canadian Tire), cage paper 
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(Biology building basement), timer, 50 mL Falcon tubes filled with ~30 mL 
formaldehyde for immunohistochemical organ storage. 
 
2.4.2. Tissue Collection for Immunohistochemistry and Biochemical Assays 
To prepare the anesthetic chamber, the oxygen tank was turned on and the rat was 
placed inside.  The dial on the isoflurane (Chemical Control Centre, Ref. 537401) 
apparatus was turned to 5 and the rats were kept in the anesthetic chamber until they 
appeared asleep (approximately 2-3 minutes).  The animals were then transferred to the 
dissection tray and an anesthetic mask was put over the nose.  The skin under the forearm 
was pinched to confirm the rat was asleep and could not feel pain. 
Ethanol was used to moisten the fur on the abdomen and an incision was made 
just under the xiphoid process of the sternum, vertically up to the neck on the ventral 
aspect of the rat.  A 255/8 gauge needle (BD Precision Glide Needle, Biology stockroom, 
Ref. 00100370) with a 1mL syringe (BD, Biology stockroom) was inserted into the heart 
and used to obtain ~1 mL of blood, which was then stored on ice in plasma separator 
tubes (BD Biosciences Microtainer, Plasma Separator Tubes with Lithium Heparin, Ref. 
365958).  To perfuse the rat, a 12-gauge needle (Biology stockroom) was inserted it into 
the left ventricle of the heart pointing up towards the left atrium.  A small nick was made 
to the right atrium.  Tyrode’s buffer [8.76 g NaCl, 0.298 g KCl, 0.222 g CaCl2, 2.603 g 
HEPES, 1 g dextrose, 1 g NaHCO3 and 0.06 g Na2HPO4 4H2O per litre of dH2O] 
containing 114.28 mg of heparin (Sigma-Aldrich, Cat. No. H3393), to prevent blood 
clotting, was gravity fed through hosing and the 12-gauge needle.  The anesthetic mask 
was taken off at this point.   
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Once the fluid emerging from right atrium turned clear and there was 
discoloration of the liver (identified by snipping the edge if not visible otherwise), the 
Tyrode’s buffer was switched to 10% buffered formaldehyde diluted with PBS [8 g NaCl, 
0.2 g KCl, 2.68 g Na2HPO4•7H2O and 0.24 g KH2PO4 in 800 mL of dH2O, pH = 7.4]. 
Perfusion was continued until limbs (including neck) became rigid.   
The animal was then decapitated by guillotine and the heart, kidney, liver and 
brain were collected.  Samples that would be used for immunohistochemistry were fixed 
by placing into 10% buffered formaldehyde filled falcon tubes for 24 hours at 4oC.  Those 
that would be used for biochemical assays were put into 5 mL Nalgene cryoware 
cryogenic vials (VWR, Cat. No. 5000 0050), snap frozen in liquid nitrogen and then 
stored at -80oC.  Blood samples were spun at 4,000 r.p.m.; the serum was collected and 
transferred to a 1.5 mL microcentrifuge tube (Axygen, Cat. No. 311-08-051), and stored 
at -80oC. 
 
2.4.3. Brain Harvesting 
 After decapitation, the scalp is first removed and the sides of the skull loosened at 
the base with scissors. The skull was then removed with pliers by moving down the sides 
and then across the top of the head.  The curved forceps were used to pull the meninges 
out of the way and the brain scooped out (using gravity and very gentle force).  For 
biochemical assays, the cerebellum was removed; the rest of the brain was sectioned 
down the midline and separated into two hemispheres. 
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2.5. Immunohistochemistry 
2.5.1. Immunohistochemical Reagents 
 The following materials and reagents were used for immunohistochemistry:  
microscope cover class 22 x 60 (UltiDent Scientific, Biology Stockroom, 170-C2260), 
universal protein block, serum-free, ready to use (DAKO, Ref. X0909), antibody diluent 
(DAKO, Ref. S0809), diamino benzamidine (DAB) (Sigma, Cat. No. D8001-5G), 
Vectastain Elite ABC Kit containing goat serum blocking solution and avidin biotinylated 
horse-radish peroxidase complex (ABC reagent) (Vector Laboratories, Cat. No. PK-
6101), DAB peroxidase substrate kit (Vector Laboratories, Cat. No. SK-4100), Cytoseal 
(Thermo Scientific, Ref. 8310-16). 
 Antibodies: Affinity purified rabbit anti-tyrosine hydroxylase polyclonal antibody 
(1:1000, Pel-Freez, Cat. No. P40101), rabbit anti-glial fibrillary acidic protein polyclonal 
antibody (1:500, ABCAM, Cat. No. ab7260, Lot #6-R20948-a) and   goat anti-rabbit 
biotinylated secondary antibody (Elite ABC kit, Vector Laboratories, Cat. No. PK-6101). 
 
2.5.2. Dehydration and Paraffin Embedding 
 To prepare the rat brains for dehydration, after 24 hours the 10% buffered 
formaldehyde was exchanged for 70% ethanol and incubated overnight at 4oC.  The 
brains were then dehydrated by an ethanol gradient: 30 minutes in 70% ethanol, 1 hour 
each in 80% and 95% ethanol and 1 hour (x3) in 100% ethanol.  The brains were then 
incubated in xylene for 40 minutes (x2) and then paraffin wax overnight in a 60oC water 
bath (Isotemp 202, Fisher Scientific). 
 The forebrain (at the optic chiasm) was removed, guided by a brain matrix (Ted 
Pella Inc, Cat. No. 15054) and the rest of the brain was transferred to metal moulds (Lab 
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Tek Plastic Co, patent number 2996762).  It was then covered by paraffin wax (VWR, 
Cat. No. 72050-030) supported by plastic embedding moulds (VWR, Cat. No. 25602-
766) and left to dry. 
 
2.5.3. Tissue Sectioning 
 Midbrain tissue sections were cut on a microtome (Heidelberg HM 320), fitted 
with disposable microtome blades (Triangle Biomedical Sciences, Cat. No. DMB-LP) at 
40 µm initially (30 µm later on) spanning the entire substantia nigra region (-4.56 mm to 
6.60 mm Bregma).  Sections were cut at 20 µm spanning the latter half of the 
hippocampus region (-4.56 mm Bregma) and sections cut at 20 µm spanning the latter 
half of the putamin (6.60 mm Bregma). 
 
2.5.4. Slide Preparation 
Two types of slides were used; Superfrost plus (Fisher, Cat. No. 12-550-18) and 
normal microscope slides (Biology stockroom, reference number 00100418).  The 
Superfrost slides were used as is for thinner sections (20 µm), tissue was placed into a 
water bath at 43oC and scooped up with the slides.  The regular microscope slides were 
used for thicker 30 µm and 40 µm sections. 
Since the thicker sections did not stay on the Superfrost slides, the normal 
microscope slides were prepared multiple ways to determine the best method for adhesion 
of the brain tissue.  The preparation that was the most successful included using 30 µm 
sections and coating the slides with egg white albumin (egg whites from the grocery 
store). The albumin was applied to the slides by gloved finger and then left to dry for 2 
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hours in a dust free chamber. Once the slides were dry, the 30µm sections were picked up 
from a distilled water bath set at 40 oC and left in a dust free chamber to dry overnight 
(~16 hours) at room temperature.  
 
2.5.5. Bright-field Immunohistochemistry using 3,3’-diaminobenzidine (DAB) 
 Due to the purchase of new Stereologer software, the protocol for bright-field 
immunohistochemistry using 3,3'-diaminobenzidine (DAB) was modified from previous 
years.  Although optimum standardization of this protocol is still taking place, the 
following method proved satisfactory. 
 All solutions were placed in glass Coplin jars (donated by NRC in Ottawa) and 
slides were submerged in glass Coplin jar baskets (donated by NRC in Ottawa) unless 
otherwise specified. 
 After dehydration, the tissue sections were deparaffinized by submerging them in 
xylene (2x5 minutes); fresh xylene was exchanged after three uses.  Sections were then 
rehydrated using an ethanol gradient (5 minutes in 95% ethanol, 5 minutes in 70% 
ethanol), then 5 minutes in dH2O.  Next, slides were washed in tris-buffered saline (TBS) 
[2 x 5 minutes; 12 g of Tris-HCl, 17 g of NaCl and 1 L of dH2O, pH = 7.2], incubated in 
3% H2O2 for 40 minutes to block endogenous peroxidases and washed again in TBS (3 x 
5 minutes).  The slides were first blocked with avidin and biotin for 15 minutes each 
according to the manufacturer’s protocol (Vectastain Elite ABC Kit, Vector 
Laboratories).  Next, they were blocked with the goat serum blocking solution for 30 
minutes and then with universal serum-free protein block for another 30 minutes.  The 
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slides were incubated with primary antibody with 1% Triton in antibody diluent overnight 
at 4oC in a humid chamber.  
 The next day slides were washed 3 x 5 minutes in TBS and then incubated in 
secondary antibody for 1.5 hours.  After another wash in TBS (2 x 7 minutes), ABC 
reagent was applied for 45 minutes.  The slides were washed again with TBS (3 x 5 
minutes) and DAB was applied drop-wise to each tissue section.  A colour change to dark 
brown was visually monitored until the SN region could be identified (this was 
supplemented by looking on the microscope).  The reaction was stopped by submerging 
the slides in dH2O (3 x 5 minutes) and then washed again in TBS (3 x 7 minutes).  The 
sections were dehydrated using 95% ethanol (2 x 5 minutes) and xylene (2 x 5 minutes).  
The slides were then cover slipped using Cytoseal. 
 
2.5.6. Stereologer Software 
 To obtain statistically significant data, Stereologer software was purchased from 
Disector (Stereology Resource Center, Inc., Maryland, US) and used to count the TH 
positive (DA neurons) in the substantia nigra.  Out of approximately 40 midbrain sections 
(-4.56 mm 6.60 mm Bregma), a total of ten sections were selected (every fourth) as a 
representation of the SN region.  These sections were then counted systematically using 
the software prompts.  See Appendix E for screen shots and step-by-step instructions. 
 
2.6. Biochemical Assays 
2.6.1. Biochemical Reagents 
 The following reagents were used for brain tissue homogenization and sample 
preparation: homogenization buffer [50 mM Tris-HCl, 0.15 mM NaCl, 10 mM EDTA, 
 42 
1% TritonX-100, 1 mM PMSF, 1µg/mL pepstatin A and 1 µg/mL leupeptin, pH = 7.5], 
Phosphate-buffered saline (PBS) [8 g NaCl, 0.2 g KCl, 2.68 g Na2HPO4 7H2O and 0.24 
g KH2PO4 in 800 mL of dH2O, pH = 7.4], 4X loading dye [50 mM Tris-HCl, pH = 6.8, 
100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue and 10% glycerol], bovine 
serum albumin (BSA) (Sigma-Aldrich, Cat. No. A7906), Bio-Rad protein dye assay 
reagent (Bio-Rad Laboratories, Cat. No. 500-0006). 
The following reagents were used for Western blot assays: 12% SDS-PAGE 
resolving gel [2.15 mL of dH2O, 1.5 mL of 40% acrylamide, 1.25 mL of 1.5M Tris (pH = 
8.9), 50 µL of 10% SDS, 50 µL of 10% APS and 8 µL of TEMED], 12% SDS-PAGE 
stacking gel [1.75 mL of dH2O, 300 µL of 40% acrylamide, 400 µL of 0.5M Tris (pH = 
6.7), 25 µL of 10% SDS, 25 µL of 10% APS and 5 µL of TEMED], running buffer [14.4 
g of glycine 1 g of SDS, 3 g of Tris HCl, 1 L of dH2O]. 
Antibodies: Affinity purified rabbit anti-tyrosine hydroxylase polyclonal antibody 
(1:1000, Pel-Freez, Cat. No. P40101), rabbit anti-glial fibrillary acidic protein polyclonal 
antibody (1:500, ABCAM, Cat. No. ab7260, Lot #6-R20948-a), rabbit anti-brain derived 
neurotrophic factor (1:1000, Scanta Cruz Biotechnology, Cat. No. sc-546 Lot #I2309 or 
Cat. No. sc-20981 Lot #J1810), rabbit anti-interleukin-β1(H-153) polyclonal antibody 
(1:1000, Santa Cruz Biotechnology, Cat. No. sc-7884), affinity purified rabbit anti-nerve 
growth factor (M-20) polyclonal antibody (1:1000, Santa Cruz Biotechnology, Cat. No. 
sc-549), affinity purified rabbit anti-glial derived neurotrophic factor (D-20) polyclonal 
antibody (1:500, Santa Cruz Biotechnology, Cat. No. sc-328), series of rabbit anti-
LRRK2 antibodies (Michael J. Fox Foundation, Cat. No. c68-7, c81-8, c5-8, c69-6, c41-
2, Epitomic, Inc.), rabbit anti-beta actin antibody (Santa Cruz Biotechnology, Cat. No. sc-
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81178 Lot #131809), rabbit anti-tubulin antibody (Santa Cruz Biotechnology, Cat. No. 
sc-9104) and polyclonal goat anti-rabbit HRP conjugate (DAKO, Cat. No. P0448). 
 
2.6.2. Tissue Homogenization 
 Animals that were snap frozen for biochemical analysis were thawed on ice, 
weighed, and minced with scissors.  They were then homogenized in 10 times the volume 
(10 mL of buffer for 1 g of tissue) in ice-cold homogenization buffer (pH = 7.5) for 30 
seconds three times with 20-second intervals.  The homogenates were then centrifuged 
(Jouan CR3i) at 3,000 r.p.m. for 10 minutes in a T40 swing bucket rotor at 4oC.  The 
supernatant (cytoplasmic fraction), was transferred to a 50 mL Falcon tube and protease 
inhibitors were added (LeuPep 1 µL/mL, PepA 1 µL/mL and PSMF 10 µL).  The samples 
were then aliquot (500µL) into microcentrifuge tubes and stored at -80OC for future 
biochemical assay use. 
 
2.6.3. Sample Preparation 
To prepare samples for SDS-PAGE/Western blots, brain tissue homogenates were 
thawed on ice, sonicated for 10 seconds (level 4) and spun on a Biofuge 15 centrifuge 
(Heraeus Instruments) at max r.p.m. for 5 minutes at 4oC (in the cold room).  The protein 
content was then estimated using the Bradford Assay (described below).  Samples were 
aliquot by adding 20 mg of tissue homogenate to PBS (pH = 7.4) and 4X loading dye for 
a total volume of 20µL.  They were heated at 95oC on a heat block for 7 minutes and 
stored at -20oC. 
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2.6.4. Bradford Assay 
To estimate the protein concentration in the tissue homogenate samples, a 
Bradford Assay was performed using the Bio-Rad Laboratories protocol. A standard 
curve was established using 1 mg/mL BSA for known concentrations ranging from 0.002 
mg/mL to 0.025 mg/mL.   
For protein estimation 2 µL of sample tissue was added to 798 µL of dH2O and 
200 µL of Bio-Rad protein assay reagent to a plastic 1 mL cuvette in triplicate.  The 
samples were mixed with a pipette and incubated at room temperature for 5 minutes.  The 
absorbance of the standards and samples were measured using a Genesys UV-Visible 
Spectrophotometer at 595 nm.  Microsoft Excel was used for data analysis. 
 
2.6.5. SDS-PAGE Western Blot 
 Protein samples were prepared as stated above, thawed, vortexed, centrifuged and 
loaded (20 µg of protein per well) onto a 12% SDS-PAGE.  The gel was run in running 
buffer until the dye front ran off the bottom of the glass plate.  The protein was 
transferred in transfer buffer [10X: 1.45 g of Tris (hydroxymethyl) base, 7.2 g of Glycine, 
200 mL of methanol and 800 mL of dH2O, pH=7.6] onto a nitrocellulose membrane for 
1.5 hours at 0.12 constant amps.   
 To insure equal loading of protein, the membrane was incubated in PonseauS [100 
mg of Ponceau, 5 mL of acetic acid and 95 mL of dH2O] for 10 minutes on a rocking 
platform (VWR, model 200).  It was then washed with dH2O until bands were visible, and 
imaged on an HP scanjet 4600 scanner.  The membrane was blocked in 5% skim milk in 
TBST [12 g of Tris-HCl, 17 g of NaCl, 1 mL of Tween, 1 L of dH2O, pH = 7.6] for 1 
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hour at room temperature on the rocking platform and then incubated in primary antibody 
with 2% skim milk overnight at 4oC on a nutating mixer (Gyromini, Labnet). 
 The next day the blots were washed with TBST (15 minutes, 3 x 5 minutes), then 
incubated in secondary antibody in 2% skim milk solution for 1 hour at room temperature 
on rocking platform.  The blots were washed in TBST, as mentioned previously and 
developed using ChemiGlow West kit as per the manufacturer’s protocol (Sigma Aldrich, 
Cat. No. C9107).  The blots were then imaged on an Alpha Innotcech Corporaation 
Imaging System. 
 
2.6.6. Glutathione Assay 
 To determine levels of oxidative stress a GSH assay was used.  Tissue samples 
were prepared as per section 5.1 describes and 2 µL of each were loaded onto a 96 well 
translucent, flat-bottomed plate (Sarstedt, Cat. No. 83-1835-300).  To each well 100 µL 
of reaction mixture [1 mM NADPH and 100 units of GSH reductase in dH2O] was added.  
The plate was then incubated for 20 minutes at 37oC. 
A standard curve was made by using 1 mM GSH and 50 µL of this was added to 
the 96-well plate along with 150 µL (to standards) and 100 µL (to samples) of 
dithiobisnitrobenzoic acid (DTNB) in 0.1 M PO4 buffer (pH = 8.0) and incubated again 
for 15 minutes at 37oC.  Endpoint absorbance at 405 nm was measured using a Wallac 
Victor3 1420 multilabel counter plate reader (PerkinElmer).  A Bradford assay was 
performed to estimate the protein concentration in each tissue sample.  The amount of 
oxidative stress was expressed in GSH per microgram of protein (g/mol) and data was 
represented using Graph Pad Prism. 
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2.6.7. Lipid Peroxidation 
 Lipid peroxidation was measured in order to determine levels of oxidative stress 
occurring in the brain of treated animals.  In 1.5 mL microcentrifuge tubes, 100 µL of 
brain tissue homogenate was added to 1 mL of thiobarbituric acid (7 g trichloroacetic 
acid, 0.185 g thiobarbituric acid, 12.5 mL of 0.25 M HCl in 37.5 mL of dH2O).  The tubes 
were incubated on a heat block at 100oC for 20 minutes with the lids open so caps did not 
pop.  Once the tubes reached room temperature, their absorbance at 535 nm was 
measured using a Genesys UV-Visible Spectrophotometer. 
A standard curve was made using 100 µM malondialdehyde (MDA), as well as a 
Bradford assay, to determine concentration.  Levels of lipid peroxidation was represented 
per microgram of protein, calculated on a Microsoft excel worksheet and displayed on 
Graph Pad Prism. 
 
2.7. Statistical Analysis 
 Unless otherwise stated, all the statistical data is represented as the mean ± SEM 
of at least three independent animals.  Statistical analysis was performed by two-way 
ANOVA tests followed by post-hoc Dunnett’s multiple comparison tests, using Graph 
Pad Prism. 
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CHAPTER III 
RESULTS 
The cause of Parkinson’s disease is still unknown, and there are currently no 
treatments for the disease beyond symptomatic relief. The aim of this study was to 
establish an environmental toxin-induced animal model of Parkinson’s disease that shows 
its progressive pathogenesis, as well as to quantify the bioavailability of a water-soluble 
formulation of CoQ10, and to evaluate its neuroprotection as a therapeutic treatment 
against Parkinson’s disease. 
 
Troubleshooting 
The majority of time on this project was put into standardizing the 
immunohistochemical methodology for the Stereologer software.  Please see Appendix A 
for a summary of the tissue staining techniques used throughout these studies. 
 
3.1 Paraquat Toxicity Suggests Progressive Dopaminergic Neuronal Cell Death 
Parkinson’s disease is both progressive and chronic, with the progressive loss of 
DA neurons in the SNpc as the most apparent contributing factor.  Normal aging humans 
lose many brain cells throughout the course of their lives, including DA neurons; 
however, those with PD lose them at an alarming rate.  Therefore, to create a realistic 
model of Parkinson’s disease, the effect of paraquat toxicity on the brains of Long Evans 
hooded rats, specifically the progressive loss of DA neurons in the substantia nigra, were 
assessed. 
As mentioned, tyrosine hydroxylase is the rate-limiting enzyme responsible for 
converting tyrosine into dihydroxyphenylalanine (DOPA), which is the first step of 
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dopamine synthesis in neurons (Figure 1).  Tyrosine hydroxylase has also been shown to 
decrease after dopaminergic insult (Emborg, 2004), and thus a good marker for DA 
neurons. Tyrosine hydroxylase positive neurons in the substantia nigra region of the 
midbrain, spanning approximately Bregma -4.56 mm to Bregma 6.60 mm (Paxinos & 
Watson, 2005) of both paraquat-injected and saline-injected rats were counted using 
stereological software.  Stereological software was also used to compare the substantia 
nigra volume and mean cell volume of DA neurons of animals receiving paraquat 
injections with those that received saline injections (control animals).   
Counting of the TH positive neurons in the substantia nigra revealed a 15% 
decrease of DA neurons when comparing PQ-injected to the saline-injected control 
animals that were sacrificed 48 hours after injections (Figure 18a).  Furthermore, after 2 
weeks and 1 month post-paraquat injection, the number of TH positive neurons decreased 
approximately 40% (Figure 18a).  Also observed was a 50% decrease in SN volume after 
both the 2-week and 1-month time points compared to control (Figure 18b).  The mean 
volume cell of DA neurons did not differ from control throughout the three time points 
(Figure 18c).  Visual representations of TH positive neurons in the substantia nigra region 
support this data (Figure 18d). Due to a low number of rats in each group (n = 2), 
statistical analysis could not be conducted. 
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Figure 18: Paraquat injections suggest progressive loss of dopaminergic neurons. a) 
Dopaminergic neurons (TH positive cells) in the substantia nigra decrease in number over 
time after paraquat injections, b) volume of the substantia nigra region of the midbrain 
shows parallel results to TH positive numbers, c) mean cell volume of TH positive 
neurons stay consistent throughout timeline, d) photomicropgraph representing TH 
positive neurons in the substantia nigra region.  Control animals were saline injected.  
Values expressed as mean ± SEM, n = 2. Scale bar = 100 microns. 
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3.2. Bioavailability and Pharmacokinetics of WS-CoQ10 
 To prepare for clinical trials, it was necessary to determine if WS-CoQ10 could be 
orally ingested, absorbed by the intestines, and delivered to the brain.  Three tissues were 
evaluated for the absorption and metabolism of WS-CoQ10 administered orally via the 
rats’ drinking water: blood plasma, liver, and brain.  This experiment was the first to 
evaluate the bioavailability of the water-soluble formulation of coenzyme Q10. 
 Rats were divided into two main groups: those that would receive a low 
concentration of WS-CoQ10 (50 µg/mL), and those that would receive a high 
concentration of WS-CoQ10 (100 µg/mL) in their drinking water.  The rats were further 
subdivided into sacrifice time (see Section 2.3.2. for clarification).  The different 
concentrations of WS-CoQ10 were used to determine which concentration was necessary 
to deliver the effective dose of the compound.  The data demonstrated that the higher 
concentration was not necessary since the lower concentration delivered very similar 
amounts of the compound to the brain tissue.  Data is not shown.  Since there was no 
difference in the levels of CoQ10 between the 50 µg/mL and the 100 µg/mL doses, the 
results for the lower concentration only are shown.   
 The water-soluble formulation of CoQ10 is a method for delivering CoQ10; 
therefore, for clarification this experimental data detects levels of CoQ10.  Results show 
that CoQ10 is absorbed into the blood plasma very quickly and efficiently.  The levels of 
CoQ10 after one hour reach approximately 80 ng/mg of protein and then decrease 
significantly to almost zero three hours after the supplemented drinking water was given 
to the rats (Figure 19a).  Results from the rat liver show that there is a substantial increase 
(100%) in the levels of CoQ10 after one hour, and a 250% increase three hours after orally 
ingesting the CoQ10 (Figure 19b).  The most significant findings of this experiment were 
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discovered with the bioavailability of CoQ10 levels in brain tissue (Figure 19c).  As early 
as one-hour post-oral administration of WS-CoQ10 results show significantly high levels 
of CoQ10 in the brains of the test animals, jumping from 150 ng/mg of protein in control 
rats to 383 ng/mg of protein.  This is more than a 150% increase in CoQ10 levels in the 
brain, which continues to increase up to 200% from control, even six hours after WS-
CoQ10 administration.  It may be noted that the lower concentration of 50 µg/mL was 
given as treatment to the rats in all other experiments conducted before, during, and after 
these results. 
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Figure 19: Bioavailability and pharmacokinetics of WS-CoQ10. a) Bioavailability of 
water-soluble formulation delivery of CoQ10 in rat plasma, b) absorption and potential 
metabolism of CoQ10 in rat liver, c) absorption of CoQ10 into brain tissue.  Control rats 
received normal drinking water only.  Values expressed as mean ± SEM and analyzed by 
ANOVA followed by Dunnett’s multiple comparison test, n = 3. 
 **p < 0.01, ***p < 0.001. 
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3.3. Injecting WS-CoQ10 Intravenously 
As a quick preliminary experiment, WS-CoQ10 was injected intravenously through 
the tail of the rats to determine the bioavailability of the compound.  This experiment was 
performed to see if WS-CoQ10 could be administered directly into the blood stream and 
compare to the results of the orally administered WS-CoQ10.  It would be easier for 
patients to take WS-CoQ10 orally, but if necessary, intravenous injection should be a 
possibility as well.  To see how quickly WS-CoQ10 could be absorbed and metabolized, it 
was delivered straight into the blood stream.   
 Due to the low priority of this experiment and limited personnel of our 
collaborators, the National Research Council of Canada (NRC, Ottawa), the HPLC 
analysis of these rat samples was not completed.  Therefore, no results were given for the 
intravenous injection of WS-CoQ10. 
 
3.4. Evaluation of WS-CoQ10 as a Therapeutic Neuroprotectant 
 Previous results in this laboratory have shown that WS-CoQ10 does in fact have 
the ability to protect DA neurons both in vitro and in vitro models of Parkinson’s disease 
when given prophylactically (McCarthy et al., 2004; Somayajulu et al., 2005; 
Somayajulu-Nitu et al., 2009). While a prophylactic approach does have benefits towards 
preventing PD, most people do not know they have Parkinson’s disease until more than 
50% of their DA neurons are lost and the symptoms of PD begin to show.  Therefore, it is 
more beneficial and realistic to treat Parkinson’s disease after clinical diagnosis 
(therapeutically).   
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3.4.1.  Dopaminergic neurons are protected by WS-CoQ10 
To evaluate WS-CoQ10 as a therapeutic agent, animals were given WS-CoQ10 in 
their drinking water immediately after receiving their fifth/last injection of paraquat (see 
Section 2.3.4. for details of experimental design).  Rat brain tissue samples were obtained, 
sectioned, immunostained using anti-tyrosine hydroxylase as a marker of dopaminergic 
neurons and counted in the substantia nigra, using stereological methods previously 
mentioned.  The results of these TH positive neuronal counts show that DA neurons in the 
substantia nigra decrease significantly in number (60%), when subjected to paraquat toxic 
insult compared to control rats (Figure 20a).  However, when these rats were given WS-
CoQ10 supplemented water following paraquat injections, the number of DA neurons in 
the SN decreased by only 40% compared to control rats (Figure 20a). Illustrated in Figure 
20b, control animals (Sal + H2O) had dense, darkly stained TH positive neurons, whereas 
paraquat-injected, untreated (PQ + H2O) animals had a large area lacking DA neurons.  
The most striking result is paraquat-injected, treated (PQ + WS-CoQ10) rats, in which you 
can see some loss of DA neurons, but considerably more than paraquat-injected, untreated 
(PQ + H2O) animals (Figure 20b).   
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Figure 20: Neuroprotection of dopaminergic neurons by WS-CoQ10. 
Photomicrographs of a) control rats b) paraquat-injected untreated rats and c) paraquat-
injected WS-CoQ10 treated rats, n = 7.  Scale bar = 100 microns. Values expressed as 
mean ± SEM, and analyzed by ANOVA followed by Dunnett’s multiple comparison test, 
**p < 0.01. 
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3.4.2.  Biochemical markers of oxidative stress 
 Biochemical results were obtained from brain tissue homogenates to shed light on 
the potential mechanism of WS-CoQ10 neuroprotection.  A glutathione (GSH) essay was 
conducted in order to evaluate levels of oxidative stress with and without WS-CoQ10 
treatment.  Figure 21a shows a significant decrease (40%) of reduced glutathione 
following paraquat injections compared to control, implying an increase in reactive 
oxygen species.  Rats treated with WS-CoQ10 supplemented water showed only a 20% 
decrease in reduced glutathione. 
A lipid peroxidation assay was also performed to assess the level of oxidative stress 
between control, paraquat-injected and WS-CoQ10 treated rats.  Figure 21b shows lipid 
peroxidation increase by approximately 50% in paraquat-injected rats, and approximately 
25% in WS-CoQ10 treated rats. 
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Figure 21:  Markers of oxidative stress.  a) Levels of reduced glutathione, n = 8, and b) 
levels of lipid peroxidation compared to percentages of control, n = 3.  Values expressed 
as mean ± SEM, and analyzed by ANOVA followed by Dunnett’s multiple comparison 
test, *** p < 0.001. 
a) 
b) 
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3.4.3. Behavioural Results 
Behavioural data was collected before, during and after paraquat injections (see 
Section 2.3.4. Figure 17 for experimental timeline).  These tests were conducted by Dr. 
Cohen’s laboratory and Dr. Cohen consolidated results.  Figure 22 illustrates that on the 
first day of testing rats injected with paraquat and untreated spent approximately 100 
seconds climbing down the role, compared to paraquat-injected, treated (WS-CoQ10) rats 
that spent only 45 seconds doing so, less than half the amount of time.  Rats were 
subjected to this pole test only after paraquat injections. 
 A second behavioural test was the vertical climb-up test; also known as the turn 
around test (Chapter II, 3.4).  The rats were subjected to this test before, during and after 
paraquat injections.  Figure 23 illustrates that post-paraquat injections, animals that were 
untreated spend approximately 16 seconds reaching the platform; whereas WS-CoQ10 
treated rats took 9 seconds (approximately 1.8 times quicker than untreated). 
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Figure 23: Vertical Climb-up Test.  Time taken for control (blue), untreated (red), and 
treated (green) rats to climb up to a platform.  n = 27. 
 
Figure 22: Pole Test. Time for control (blue), untreated (red) and treated (green) rats to 
climb down a pole.  Tests conducted post-paraquat injections.  n = 27. 
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CHAPTER IV 
DISCUSSION 
4.1. Overview 
The current study was designed to induce Parkinsonian symptoms in a rat animal 
model using the herbicide, paraquat.  Intervention with a water-soluble formulation of 
coenzyme Q10 was introduced as therapeutic treatment for slowing or halting the 
progression of the disease by protecting dopaminergic neurons.  The results of this study 
confirmed paraquat as an environmental toxin able to induce progressive dopaminergic 
cell death in a rat model of Parkinson’s disease, and treatment with WS-CoQ10 was able 
to provide neuroprotection.  There were also high levels of CoQ10 found in the brain, 
liver, and blood plasma of rats that were given water-soluble CoQ10 in their drinking 
water, demonstrating the ability of the compound to cross the blood brain barrier. 
 
4.2. Animal Models of Parkinson’s Disease 
The pathogenesis of Parkinson’s disease is not clearly understood; there are many 
underlying factors from environmental to genetic and everything in between.  Therefore, 
when studying a neurodegenerative disease, such as Parkinson’s, suitable laboratory 
models are needed.  While cell culture-based assays are an informative approach to study 
the basics of the disease and potential treatment at the cellular level, in vitro observations 
are often not akin to what happens in complex organisms, such as the human brain.  On 
the other hand, human subjects are not readily available for brain research; therefore, 
feasible animal models must be designed to relate as closely as possible to the human-
based disease.  As always, when conceiving an animal model for neurodegenerative 
studies, there are both benefits and drawbacks, such as reproducibility, incomplete 
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pathogenesis and the ability to incorporate transgenes, to name a few.  Until there is a 
“perfect” animal model for studying Parkinson’s disease, the appropriateness of the 
model selected is based upon objectives and conceivable outcomes of the experiment. 
In 1915, Long and Evans were the first to cross female, white Wistar rats with 
male, wild gray rats creating what are now called Long Evans Hooded rats.  These rats 
are general multipurpose models, mainly used for behavioural studies (Charles River 
Laboratories, Inc., criver.com), including behavioural deficits in animal models of 
Parkinson’s disease (Rane & King, 2011; Courtiere et al., 2011; Klein et al., 2011).  The 
Long Evans Hooded rat has long established protocols for behavioural studies in Dr. 
Cohen’s laboratory at the University of Windsor Psychology department.  These rats are 
easy to handle and train, cooperative, and have more brain complexity than the mouse. 
The current neurodegenerative model developed previously by this laboratory of 
five intra-peritoneal injections of paraquat has shown to induce dopaminergic cell loss in 
the SN of Long Evans Hooded rats, without damaging major organs due to toxicity 
(Somayajulu-Nitu et al., 2009).  This has been recognized as an acceptable way of 
inducing Parkinsonian symptoms: substantia nigra dopaminergic cell loss, mitochondrial 
dysfunction, increased oxidative stress and behavioural deficits.  The only downside is 
that this model lacks the inclusion of Lewy bodies found in humans who have PD.  Since 
the aim of this study was to develop a neuroprotectant, a “fidelity model,” defined as a 
model that reproduces the maximum number of characteristics of the original disease, 
was desired (Bove & Perier, 2011). 
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4.3. Paraquat as an environmental toxin-induced model for Parkinson’s Disease 
 A number of toxins could have been used to induce Parkinsonism in a rat model; 
however, paraquat was chosen for the following reasons: i) although MPTP is an 
excellent, consistent model, rats are relatively resistant to it (Przedborski et al., 2001), 
dopaminergic cell death is not progressive, and it is a synthetic toxin that no human 
would come in contact with besides those using synthetic heroin, ii) rotenone is not very 
toxic to humans, and unstable in the environment (Bove et al., 2005); it shows non-
specific toxicity in rats, and behavioural deficits are sometimes undetectable (Klein et al., 
2011), iii) 6-OHDA does not cross the BBB and can only be administered by stereotaxic 
methods (Terzioglu & Galter, 2008; Mercanti et al., 2012).   
Paraquat, the toxin of choice, is a broadleaf herbicide used widely throughout the 
world (Dinis-Oliveira et al., 2008), although it was banned in Europe in 2007.  The most 
common exposure to paraquat occurs by ingestion, direct contact with skin, or inhalation 
in enclosed areas such as greenhouses.  After exposure, it can travel to all tissues, but is 
mostly localized in the kidneys, as well as the lungs where respiratory failure becomes the 
major cause of death (Suntres, 2002).  Studies found that paraquat as an oxidative stress 
producer is linked to PD, and exposure to paraquat not only amplifies the risk of 
developing PD, but also increases the chances of early onset (Tanner et al., 2011; Liou et 
al., 1997; Dhillon et al., 2008; Costello et al., 2009).  For these reasons, including the 
likelihood of contact, and correlation to human Parkinson’s disease, paraquat was chosen 
as the environmental toxin to induce PD in Long Evans Hooded rats. 
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4.4. Assessment of paraquat toxicity 
Parkinson’s disease is characterized by the progressive loss of DA neurons in the 
substantia nigra pars compacta.  Normal aging humans lose many brain cells throughout 
the course of their lives, including DA neurons; however, those with PD lose them in this 
region of the midbrain at an alarming rate.  The current study demonstrated that the five 
intra-peritoneal injection regime previously studied (Somayajulu, 2009), suggests a 
progressive loss of dopaminergic neurons.  Comparable to when Parkinsonian symptoms 
occur in human diagnosed PD (Jankovic, 2008), this rat model showed a 40% loss two 
weeks, as well as one month following paraquat injections compared to the control.  It is 
important to note that the lifespan of a Long Evans Hooded rat is approximately two 
years.  Assuming the life expectancy of a human is 80 years of age, it is possible to 
calculate that 48 hours is equivalent to 3 months of human life, 2 weeks is equivalent to 
1.5 years of human life and 1 month is equivalent to 3.3 years of human life.  Therefore, 
this paraquat-induced animal model of Parkinson’s disease can develop PD much slower 
(equivalent to 1.5 years in a human), than other established animal models and hence, 
more true to the real life scenario.  For instance, the MPTP model uses acute injections 
and is non-progressive showing dopaminergic neuronal loss only days after 
administration (Hattori & Sato, 2007). 
With no cure for Parkinson’s disease within the sights of this generation, post-
diagnosis treatment is the optimistic target for slowing or halting the progression of PD.  
Current experiments for assessing the therapeutic neuroprotection of WS-CoQ10 provide 
treatment immediately following paraquat injections. To further develop WS-CoQ10 for 
clinical trials, subsequent experiments may use the time points obtained from this study to 
determine when appropriate intervention with WS-CoQ10 for therapeutic treatment could 
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take place.  Sometime between two weeks and one month after the last injection of 
paraquat in an animal model may be the appropriate time (when approximately 50% of 
DA neurons are lost) to intervene with WS-CoQ10 treatment.  Using time point 
estimations mentioned above, the window for intervention with WS-CoQ10 treatment for 
Parkinson’s disease patients would be anywhere from 1 – 3 years after the time of 
diagnosis.  Repetition with additional time points would allow for a more precise 
prediction. 
This experiment is preliminary due to the fact that only two animals were used in 
each group and should be repeated in order to conduct statistical analysis.  It is important 
to keep in mind the variability that may accompany any animal model.  Rats, like 
humans, may respond to insult differently; some may cope better with the toxin than 
others, especially over time.  A larger sample of rats would be needed to account for the 
variability as is any case using an animal model. 
 
4.5. Measuring the bioavailability and pharmacokinetics of CoQ10 with a water-
soluble delivery system 
Promising human pilot trials for treatment of Parkinson’s disease with CoQ10 
showed that the compound was safe and tolerable in high doses up to 3000 mg/day, and 
slowed the progression of symptoms by 44% within eight months of treatment (Shults et 
al., 2004); however, the exact oil-soluble formulation of CoQ10 used was never 
mentioned.  The most recent phase III clinical trial for treatment of Parkinson’s disease 
with CoQ10 was terminated because no significant differences were seen between those 
taking CoQ10 and those taking a placebo (National Institute of Neurological Disorders and 
Stroke, 2011).  Therefore, to develop water-soluble CoQ10 for clinical trials it must be far 
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superior to current formulations.  It is well known that oral absorption of CoQ10 is 
negligible due to its low solubility in water (4 ng/mL)(Westesen, 2000), leading to poor 
absorption through the gastrointestinal tract and minimal amounts crossing the blood 
brain barrier.  One rat study found that only 2-3% of orally administered CoQ10 was 
absorbed (Zhang et al., 1995). On the other hand, the water-soluble formulation has high 
bioavailability and can certainly cross the BBB; results from the bioavailability study 
show that there are much higher levels of CoQ10 found in the blood plasma (8000% 
increase), liver (100% increase) and most importantly the brain (165% increase) after one 
hour of drinking WS-CoQ10 treated water compared to controls.  
Much research has been devoted to improving the delivery of CoQ10. Oil 
suspensions, powered formulations, self-emulsified drug delivery systems, and 
nanoparticle technology are all examples.  Some of these formulations have increased 
bioavailability (Kalenikova et al., 2008), and have shown to significantly increase CoQ10 
levels in brain tissue in mice (Matthews et al., 1998; Smith et al., 2006). 
CoQ10 absorption is similar to that of α-tocopheryl (vitamin E) because of its 
lipophilic characteristics.  Once orally administered CoQ10 reaches the gastrointestinal 
tract, it emulsifies CoQ10 and creates a micelle, allowing it to be absorbed.  After 
absorption, chylomicrons transport CoQ10 into the blood stream via the lymphatic system 
(Katayama & Fujita et al., 1972).  The water-soluble formulation developed by NRC uses 
polyoxyethanyl α-tocopheryl sebacate acid (PTS, polyethelene glycol and vitamin E) 
non-covalently linked to CoQ10 that form nanomicelles in aqueous solutions (Section 
1.8.3.).  This formulation is enhanced three-fold: i) consumption is made easier by 
solubilization in aqueous media, ii) vitamin E is present in the formulation, and iii) it is 
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already in nanomicelle form.  This may facilitate CoQ10 absorption by the intestines and 
increase plasma CoQ10, and increase the capacity to reach brain tissue, since higher 
plasma CoQ10 concentrations are necessary to facilitate uptake by peripheral tissues 
(Kwong et al., 2002).  
Recent studies with CoQ10 found that the optimal dose needed to see 
neuroprotective effects was 200 mg - 1600 mg/kg/day in mice (Cleren et al., 2008).  This 
correlates to 14 g - 114 g/day for a 70 kg person.   However, during the phase III clinical 
trials of CoQ10, a maximum amount of 3.0 g/day was given to participants (National 
Institute of Neurological Disorders and Stroke, 2011).  The FDA has approved 14 g/day 
for human consumption, but this dose was never tested.  Furthermore, 14 g/day is quite a 
sizeable amount for daily consumption.  The 50 mg/mL concentration of WS-CoQ10 
supplemented drinking water that was given to rats in this current study translates to 
approximately 6 mg/kg/day (calculated from average animal weights and average amount 
of WS-CoQ10 consumed, data not shown), and was readily available in brain tissue.  This 
translates to 0.42 g/day for a 70 kg person, a much lower and realistic effective dose than 
those used in current clinical trials. 
Further pharmacokinetic experiments should be conducted to determine the time 
point at which the supplemental CoQ10 has fully left the system of the individual.  The 
time points presently selected revealed levels of CoQ10 still increasing in brain tissue after 
6 hours.  CoQ10 orally administered to humans showed two peaks in the serum occurring 
at six hours and 24 hours in pharmacokinetic studies (Spindler et al., 2009).  The second 
peak may be potentially due to liver secretion of CoQ10 after uptake.  Extending time 
points from to 20 hours or even days may determine when subsequent doses are needed, 
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evaluate the lasting effects of CoQ10, and measure plasma levels to see if there is a 
threshold to CoQ10 absorption. 
 
4.6. Evaluation of the efficacy of WS-CoQ10 as a therapeutic neuroprotective agent 
It is understood that CoQ10 treatment of PD cannot cure nor reverse the adverse 
affects of PD, but rather halt the progression and protect the remaining DA neurons after 
clinical diagnosis.  Previous studies have shown neuroprotection by WS-CoQ10 when 
given prophylactically (Somyayjulu-Nitu et al., 2009); therefore, the next step is to 
administer WS-CoQ10, as a therapeutic agent to more closely resemble the real-life 
scenario. 
Two important studies have shown the neuroprotective of effects of CoQ10 in an 
MPTP mouse model by reducing damage to dopaminergic neurons, maintaining levels of 
striatal dopamine, and increasing mitochondrial CoQ10 (Beal et al., 1998; Cleren et al., 
2008). However, these models and many others treated toxic insult in a preventative 
manner (prophylactically), rather than treating after the toxic insult (therapeutically); 
hence, this may be the first therapeutic report of CoQ10 neuroprotection.  Results from 
paraquat-injected, therapeutic WS-CoQ10 treated rats indicate a loss of DA neurons due to 
paraquat toxicity (60% decrease), but was not as extensive in those who received CoQ10 
supplemented water (30% decrease).  Supporting biochemical assays showed decreased 
levels of GSH (45%) in paraquat-injected animal groups and increased GSH levels in 
treated rats (20% decrease).  Since glutathione combats reactive oxygen species, this must 
mean WS-CoQ10 treatment can offer additional antioxidant duties, thus reducing the need 
of GSH, and accounting for the reduction of glutathione levels.  Behavioural studies show 
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that paraquat induced a reduction in motor ability, which was alleviated by therapeutic 
treatment with WS-CoQ10. 
 
4.7. Potential mechanisms of WS-CoQ10 Neuroprotection 
Recent studies have found that patients with Parkinson’s disease have lower levels 
of CoQ10 in their blood (Mischley et al., 2012).  It may be that a threefold mechanism is 
responsible for the neuroprotective effects of WS-CoQ10 in an animal model of PD.  First, 
CoQ10 acts as a mitochondria stabilizer that effectively shuttles electrons between 
complexes of the ETC, and in doing so increases the efficiency of ATP output.  By not 
allowing electrons to leak out and produce reactive oxygen species with nearby 
molecules, such as molecular oxygen, mitochondrial membrane potential is maintained.  
When membrane potential is kept intact no pro-apoptotic elements are released; therefore 
providing no incentive for apoptosis to occur. 
Some speculate that neuroprotection with WS-CoQ10 may increase viability in 
cells that should routinely die by apoptosis, and consequently could initiate cancer.  It is 
known that oxidative stress is a major contributing factor in developing Parkinson’s 
disease; if DA neurons are programmed to die via apoptosis, they will do so independent 
of oxidative stress. 
 The second is that CoQ10 can act as an antioxidant.  As mentioned previously, 
CoQ10 transports electrons along the electron transport chain; therefore it is a reducing 
agent that can quench reactive oxidative species by accepting radical electrons.  Since 
there is increased oxidative stress in PD patients, it is logical that CoQ10 could be used to 
combat it. Vitamin E is also a large component of the water-soluble formulation that can 
also act as antioxidant for oxidative stress.  In fact, in humans, vitamin E has been shown 
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to lower the risk of developing Parkinson’s disease, delaying the need for L-dopa 
treatment in PD patients, and exhibiting some neuroprotective effects (Khanna et al., 
2005; Bostanci et al., 2010; Chao et al., 2012).  Also, animals deficient in Vitamin E were 
more susceptible to the toxic effects of paraquat, but additional supplementation to non-
deficient animals did not provide significant protection (Suntres, 2002).  It has been 
suggested that the insolubility of vitamin E might contribute to its ineffectiveness.   
The third mechanism of neuroprotection may be by activating glial cells, 
especially astrocytes.  Astrocytes are known to produce neurotrophic factors and increase 
levels of GSH in order to combat ROS production due to toxic insult.  Cell culture studies 
using fetal rat cortical neurons discovered that cell viability increased when subjected to 
paraquat, by co-culturing astrocytes with the cortical neurons.  These astrocytes increased 
the levels of GSH that in turn reduced ROS production (Rathinam, 2012).  Their findings 
coincide with the GSH levels found in rats that were either given WS-CoQ10 treatment or 
non-supplemented drinking water after paraquat-injection. 
Neurotrophic factors such as BDNF, GDNF, NGF and CDNF have all been shown 
to contribute to neuronal support and growth.  However, they were found in extremely 
variable amounts in rat brain tissue homogenates of those treated and untreated with WS-
CoQ10 in this study (data not shown).  Specifically concerning GDNF, levels of this 
neurotrophic factor obtained by stereotactic methods in human brains were equal between 
control and PD patients (Mogi et al., 2001).  This could mean that the disease does not 
affect the amount of GDNF present.  Then again, GDNF is still a good candidate as a 
therapeutic agent for PD because of its positive neurotrophic effect on DA neurons. In 
contrast, levels of BDNF and NGF in human brains were much lower in PD patients than 
control, specifically in the nigrostriatal regions (Mogi et al., 1999).  If it were possible to 
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increase levels of these neurotrophic factors with WS-CoQ10 it would surely help protect 
DA neurons.  Supporting studies such as transfecting astrocytes with the transcription 
factor Pitx3, which is expressed mainly in DA neurons in the SN, causes them to up-
regulate BDNF and GDNF and protect DA neurons from toxic injury (Smidt et al., 1997; 
Yang et al., 2008).  
 
4.8. Future Studies 
The majority of the time and effort put into this project was in an effort to 
standardize a new protocol for bright field microscopy on the Stereologer software.  Now 
that it has been standardized to satisfaction, these experiments should be repeated with a 
larger number of rats to obtain statistically significant data.  This study clearly shows that 
WS-CoQ10 can provide neuroprotection to dopaminergic neurons in the substantia nigra, 
and that it has high bioavailability.  Next, it is important to see what happens when some 
of the parameters of these experiments are changed, such as those discussed below.  
These types of studies will be required to progress WS-CoQ10 towards clinical trials. 
Since Parkinson’s disease is an age related neurodegenerative disorder, repeating 
therapeutic WS-CoQ10 treatment on aged rats would better reflect the real life scenario of 
the disease.  The rats used in these current studies are approximately five months old at 
sacrifice.  Aged rats would have to be at least 12 months old to signify old age, which is 
comparable to onset of PD in humans, since early onset is defined as developing PD 
before 40 years of age (Poorkaj et al., 2005).  Investigation of whether age affects the 
severity of paraquat toxicity on dopaminergic neurons with prophylactic treatment using 
WS-CoQ10 was conducted revealing that aged rats showed a greater loss of TH positive 
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(Somayajulu-Nitu, 2009).  Therefore, it would be essential to examine the efficacy of 
neuroprotection from WS-CoQ10 in a therapeutic manner with aged rats.  
The purpose of the paraquat toxicity study was to determine when an appropriate 
time for intervention with WS-CoQ10 would be most realistic and effective.  After 
repeating that particular experiment to gain better statistical data, a subsequent study 
should be conducted by delaying WS-CoQ10 intervention until the appropriate time 
indicated from the first experiment.  This study would also more realistically reflect the 
scenario and time of PD diagnosis for human patients. 
From the perspective of the stakeholders funding this project (Michael J. Fox 
Foundation), a dose-dependent study of WS-CoQ10 is necessary for preclinical 
development.  Previous studies have examined paraquat toxicity in various rat tissues 
(Somayajulu-Nitu, 2009), but evaluation of potential toxicity of WS-CoQ10 did not 
accompany this data.  Therefore, a study should include WS-CoQ10 doses higher (2x, 5x, 
10x, etc.) than are currently being used (6 mg/kg), and tissue sent to pathologists for 
analysis to see if there is toxicity due to high concentrations of CoQ10.  Alternatively, 
studies on lower doses of WS-CoQ10 should also be conducted.  It would benefit business 
partners (more cost-effective) and patients (a smaller amount to ingest) alike, if less of the 
compound is needed to show neuroprotection of DA neurons. 
Another important component of the overall project is to develop a therapeutic 
treatment regime for WS-CoQ10 to be used as a nutroceutical to slow or halt the 
progression of PD.  An intervention-withdrawal experiment would assess WS-CoQ10 
neuroprotection, when treatment is removed for a period of time.  The intervals and 
duration of withdrawal should be variables independently examined, to determine if 
neuroprotection is temporary or continuous.  Results from these experiments should 
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establish if it is essential for patients to consume WS-CoQ10 throughout their lives, or on 
a set schedule. 
The mechanism of neuroprotection of WS-CoQ10 still needs to be elucidated, 
including the role of mitochondria and oxidative stress, as well as neuroinflammation.  So 
far, it has been identified that astrocytes are activated by WS-CoQ10 treatment.  This can 
be looked into further by probing brain tissue samples (western blot analysis and 
immunohistochemical methods) with glial fibrillary acid protein (GFAP), which identifies 
activated astrocytes.  Identifying which neurotrophins and cytokines are elevated or 
diminished during paraquat-inducted toxicity and WS-CoQ10 neuroprotection may cause 
inspiration for further initiatives with experimental design.  While results from western 
blot analysis for levels of neurotrophins in brain tissue homogenates have been too 
variable to be deemed credible, other techniques such as ELISA and microarrays should 
be sensitive enough to eliminate any variability.   
It should be addressed whether WS-CoQ10 acts directly to reduce paraquat or 
indirectly by reducing paraquat-induced reactive oxygen species.  Measuring levels of 
ROS by in vitro ROS assays using tissues homogenates would allow for a comparison 
between paraquat-injected and WS-CoQ10 treated rat samples.  If WS-CoQ10 is acting 
directly on PQ, the levels of ROS should increase in WS-CoQ10 treated samples 
compared to the control.  Assessment of the three compounds: WS-CoQ10, O2, and PQ, to 
see if there is a higher propensity for reducing one over the other could be done by 
measuring reduction potential (Eh).  This is a measure, in volts, of the tendency of a 
chemical species to acquire electrons by using reference electrodes.  WS-CoQ10 may also 
act by stabilizing mitochondria; thus, components that are released during cell death 
(cytochrome c, AIF, etc.) could be measured as well.  
  73 
4.9. Conclusion 
This report has indicated that the environmental toxin, paraquat, induces loss of 
dopaminergic neurons in the substantia nigra region of the midbrain of Long Evans 
Hooded rats, indicating an animal model representative of Parkinson’s disease.  For the 
first time it is clearly shown that the current water-soluble formulation of coenzyme Q10 + 
vitamin E increases the bioavailability of CoQ10 found in brain tissue.  Ws-CoQ10 has also 
shown antioxidative activity in the substantia nigra following toxic insult by paraquat.  
These experiments are the first stages required to develop the water-soluble formulation 
of CoQ10 for application in therapeutic clinical trials. 
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APPENDIX A 
 
 
TYROSINE HYDROXYLASE IMMUNOHISTOCHEMISTRY PROTOCOL TROUBLESHOOTING 
 
 Old Protocol New Protocol Current Standardized 
Protocol 
Slides Super-frost Plus Albumin coated Super-frost Plus Heated 
Tissue 
Preparation 
Paraffin embedded 
Moistened with water 
Paraffin embedded 
Moistened w/ 0.1% Triton 
 Embedding matrix 
Frozen at -20oC 
Tissue Slicing Microtome Microtome Cryostat 
Section width 8 microns 40 microns 30 microns 
Tissue Sections Room temperature 45oC incubation Room temperature 
Blocking  DAKO Universal 
(15 min) 
3% H2O2 (40 minutes) 
Avidin (15 min) 
Biotin (15 min) 
Goat serum (30 min) 
Universal block (30 min) 
1% H2O2 (10 min) 
Goat serum (30 min) 
Universal block (30 min) 
Antigen Retrieval N/A 10 mM sodium citrate 
(15 min, water bath) 
N/A 
Primary Antibody Rabbit anti-tyrosine 
hydroxylase polyclonal  
(overnight, 4oC) 
Rabbit anti-tyrosine 
hydroxylase polyclonal 
(overnight, 4oC) 
Rabbit anti-tyrosine 
hydroxylase polyclonal 
(overnight, 4oC) 
Secondary 
Antibody 
Sheep anti-rabbit IgG 
FITC (1 hour) 
Goat anti-rabbit 
biotinylated (1.5 hours) 
Goat anti-rabbit 
biotinylated (1.5 hours) 
Chromogenic 
Reagent 
N/A ABC reagent (45 min, RT) 
DAB (Sigma) 
ABC reagent (45 min, RT)  
DAB (Vector Lab kit) 
Coverslip 
Mounting  
Mounting media 
containing DAPI 
Cytoseal Paramount 
Microscopy Fluorescence Bright-field Bright-field 
Cell Counting Manual Unbiased Stereologer 
software 
Unbiased Stereologer 
software 
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APPENDIX B 
 
ADDITONAL BEHAVIOURAL TESTS 
 
Rotarod 
 The rotarod test was used to evaluate the balance of WS-CoQ10 treated animals as 
per previously described (Somayajulu-Nitu et al., 2009), with the exception of a wider 
rod (10 cm diameter).  The rats were put on this rod for 2 minutes at a rate of 12 rotations 
per minute in a forward direction with a clockwise rotation.  Animals were tested once a 
day for five days before injections to allow for training.  They were also tested once 
during injections and then for five days again after injections.  A video of the rat on the 
rotarod was taken and broken down into 500 frames where the amount of time the rat 
spent facing forward, backward and turning was assessed.  The position of the nose was 
also recorded to evaluate how long the rat held its head up or down.  Software tracking 
program was used to aid in this process (7 Software, Inc, Montana, USA). 
 
Activity Chambers 
 Activity chambers were used to evaluate the general movement of the animals.  A 
3 x 1 Plexiglas chamber contained vanilla scented bedding.  Motion detectors or “photo 
beams” were set up at four different locations within the chamber.  The animals were put 
in these activity cages only once for one hour after injections.   The activity of the rat was 
divided into three different parameters and recorded: i) the time it took for the rat to cross 
from one side to the other, ii) how long it took to partially cross the chamber and iii) how 
long it spent rearing. 
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Incline Horizontal Ladder 
 A horizontal ladder with a slight incline was used to evaluate the animals’ fear of 
falling and their stability.  An apple was placed at the end for motivation to cross the 
ladder.  Metal rungs were placed along the ladder initially without any “breakaways.”  
This allowed baseline times to be recorded for each rat.  Preceding baseline training, one 
magnetic “breakaway” rung was placed within the ladder and animals were timed once 
again. In subsequent runs, animals anticipated the “breakaway” rung and tested the 
stability of each as they crossed.  Motion sensors to measure the animals’ speed collected 
data.  The rats were tested for two days during injections for baseline measurements, for 
six days after injections with breakaways and again for six days without breakaways as a 
recovery stage to gain their speed back. 
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APPENDIX C 
ADDITIONAL BIOCHEMICAL ASSAYS 
Reactive Oxygen Species (ROS) Assay 
 Detection of reactive oxygen species (ROS) was conducted on fresh liver samples 
of perfused rats.  The liver was kept on ice and washed three times with sucrose buffer 
[51.36 g sucrose, 6 mL of 1 M Tris-HCl, 600 µL of 100 mM EGTA and 10 µL of PMSF 
in 600 mL of H2O, pH = 7.4].  Approximately 1 g of tissue was homogenized in 5 
volumes of ice-cold sucrose buffer (5 mL per 1 g).  The sample was then centrifuged at 
3,500 r.p.m. for 10 minutes at 4 oC.  The pellet containing cellular debris and nuclei was 
discarded, and the supernatant was centrifuged again at 12,000 r.p.m. for 10 minutes on a 
fixed rotor.  The pellet was then re-suspended in 5 mL of sucrose buffer and centrifuged 
once again at 12,000 r.p.m. for 10 minutes.  The supernatant was discarded again and the 
mitochondrial pellet was gently re-suspended in approximately 2 mL of sucrose buffer. 
 A Bradford assay was used to determine protein concentration of the 
mitochondrial fraction of each sample so that 20 µg of protein could be added to each 
well.   Each treatment was done in triplicate in a black, flat bottom 96 well plate.  
Reaction buffer [500 µL of 1 M succinate and 125 µL of 1 M malate in 50 mL of PBS] 
was added first, then the mitochondrial sample and some wells were pre-incubated with 
WS-CoQ10 (50 µg/mL) for 5 minutes at 37oC.  After incubation additional WS-CoQ10 (as 
a control, optional) was added as well as paraquat treatment (100 µM).  Amplex Red (10 
µM) and horseradish peroxidase (HRP) were added then to all wells.  The plate was 
covered with aluminum foil and shaken briefly on a plate shaker. 
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 The plate was measured on a 96-well plate with excitation at 560 nm and emission 
at 590 nm on Soft Max Pro software.  Data was represented on Graph Pad Prism. 
 
Cytokine Array 
 A cytokine array was used to assess the relative levels of multiple cytokines 
expressed in treated rats.  Tissue samples were homogenated according to the protocol 
given by cytokine array kit from R&D Systems as was similar to the protocol above with 
the exception of using PBS (pH = 7.6) as homgenization buffer with protease inhibitors (1 
µM leupeptin, 1 µM pepstatin A and 10 µM PMSF) and 0.1% Triton X-100. 
 The Bradford assay was used to determine protein concentration and 100 µg from 
each sample was incubated with the kit detection antibody cocktail for 1 hour on a rocker 
at room temperature.  The membranes were also incubated for 1 hour at room temperature 
with blocking solution (Cytokine array kit R&D Systems).  The sample/detection 
antibody cocktail mixture was then incubated with the membranes on a rocker overnight 
at 4oC. 
 After overnight incubation, the membranes were washed with Wash buffer 
(according to manufacturers manual, Cytokine array kit R&D Systems) for 30 minutes (3 
x 10 minutes) and then incubated with Streptavidin-HRP for 30 minutes.  They were 
washed again for 30 minutes (3 x 10 minutes) and incubated with chemiluminescent 
reagent in accordance with the manufacturer’s protocol.  The membranes were imaged on 
an Alpha Innotech Corporation Imaging System and qualified for relative levels of 
fluorescence using ImageJ. 
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APPENDIX D 
ADDITIONAL EXPERIMENTAL DESIGN 
Assessment of Paraquat Toxicity Following A Series of Injections 
 
 An experiment was conducted to determine if more/longer exposure to paraquat 
increases dopaminergic neuronal cell loss in the substantia nigra.  Nineteen rats were 
divided into five groups of three (one group of four, Table A).  Animals were 
administered intraperitoneal injections of paraquat (10 mg/kg) in series: 1, 2, 3, 4 or 5 
injections, once every five days (Figure A).  Animals were sacrificed one week after their 
last injection and all brain tissue was used for immunochemistry.  No biochemical assays 
were conducted, and no behavioural experiments were conducted. 
 
Table A: Groups for the assessment of paraquat toxicity following a series of 
injections.  Rat groupings based on type of injection and number of injections before 
sacrifice. 
Number of Injections Treatment Number of Rats Sacrificed 
1 Paraquat 3 1 week post-injection 
2 Paraquat 3 1 week post last injection 
3 Paraquat 3 1 week post last injection 
4 Paraquat 3 1 week post last injection 
5 Paraquat 3 1 week post last injection 
5 Saline 4 1week post last injection 
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Figure A: Timeline for assessment of paraquat toxicity following a series of 
injections. 
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APPENDIX E 
 
STEREOLOGER SOFTWARE INSTRUCTIONS 
 
Stereologer Study Information 
Study name:  Dopaminergic neuronal cell counting 
PI: [Graduate student] 
Species: Rat 
Reference Space: Substantia nigra 
 
Stereologer Case Information 
Data collector: [person counting] 
Date: 
Group: [rat group, eg. Control, Paraquat-Injected, etc.] 
Subject: [rat identification number] 
 
Sampling Characteristics 
Slab sampling Interval: 1 
Total number of sections: [entire substantia nigra region] 
Section sampling interval: 6 (approximately 10 sections counted in total) 
Starting section: [first section to be counted] 
 
Probe Parameters  
Parameter Probe Feature 
Number Disector Tyrosine hydroxylase positive neurons 
Volume Rotator Line IUR Tyrosine hydroxylase mean cell volume 
Volume Region Point Count Substantia nigra region volume 
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Stereologer Counting 
 
 
 
 
 
 
 
 
 
1. 2. 
3. 4. 
5. 6. 
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1. Place brain tissue sample under 5x objective lens on bright-field microscope. 
2. Outline the area of interest (substantia nigra, green) using the mouse. 
3. Software places a grid overlaying the area of interest.  Selected points within the 
area of interest are green.  Change this area by selecting or deselecting red/green 
grid point using the mouse. 
4. Change objective lens to 63x and select neurons that fall within the parameters of 
the box.  Green lines indication inclusions lines; neurons touching this line are 
counted.  Red lines are exclusions lines; neurons touching this line are not 
counted. 
5. Mean cell volume is calculated by indicating boundries of the cell body.  To do 
so, click on each line where the edge of the neuron touches the green lines. 
6. Green circle represents the circumference of the cell body. 
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